



September 2022

# *artus*<sup>®</sup> SARS-CoV-2 Prep&Amp<sup>™</sup> UM Kit Instructions for Use (Handbook)



Version 1



For In Vitro Diagnostic Use on Rotor-Gene<sup>®</sup> Q MDx 5plex HRM, ABI<sup>®</sup> 7500 Fast Dx, QuantStudio<sup>®</sup> 5 Dx, cobas<sup>®</sup> z 480 or CFX96<sup>™</sup> Dx instruments



4511460, 4511469



QIAGEN GmbH  
QIAGEN Strasse 1, 40724 Hilden, GERMANY

R5

# Contents

Intended Use.....	4
Description and Principle.....	5
Pathogen information.....	5
Summary and explanation.....	6
Materials Provided.....	9
Kit contents.....	9
Kit components.....	9
Platforms and software.....	11
Materials Required but Not Provided.....	12
Consumables and Equipment.....	12
Warnings and Precautions.....	14
Safety information.....	14
Precautions.....	15
Reagent Storage and Handling.....	16
Specimen Transport, Storage, and Handling.....	16
Protocol: Sample preparation and SARS-CoV-2 Detection on the RGQ MDx 5plex HRM ...	18
Protocol: Sample Preparation and SARS-CoV-2 Detection on ABI 7500 Fast Dx.....	23
Protocol: Sample Preparation and SARS-CoV-2 Detection on the CFX96 Dx.....	28
Protocol: Sample Preparation and SARS-CoV-2 Detection on the cobas z 480.....	33
Protocol: Sample Preparation and SARS-CoV-2 Detection on QuantStudio 5 Dx.....	38
Results.....	43

Analysis on RGQ MDx 5plex HRM.....	43
Analysis on ABI 7500 Fast Dx .....	45
Analysis on CFX96 Dx .....	45
Analysis on cobas z 480.....	47
Analysis on QuantStudio 5 Dx .....	48
Interpretation of Results.....	50
Limitations.....	52
Performance Characteristics.....	53
Analytical sensitivity (Limit of detection) .....	53
Analytical specificity studies (Inclusivity and exclusivity/cross-reactivity) .....	54
Precision .....	64
Clinical performance .....	65
References .....	70
Troubleshooting Guide .....	71
Symbols.....	73
Contact Information .....	75
Ordering Information .....	76
Document Revision History.....	77

# Intended Use

The *artus* SARS-CoV-2 Prep&Amp UM Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swabs (NPS), nasal swabs and oropharyngeal swabs from individuals with signs and symptoms of infection, or individuals without symptoms or other reasons to suspect COVID-19 infection. For neat saliva specimens, the test is intended for individuals with signs and symptoms of infection or who are suspected of COVID-19.

It is intended as an aid in the diagnosis of COVID-19 in the acute phase of infection in combination with clinical observations, patient history, and epidemiological information.

The *artus* SARS-CoV-2 Prep&Amp UM Kit is to be used in a molecular biology laboratory environment by professional users, such as trained clinical laboratory personnel specifically instructed in the techniques of real-time RT-PCR and *in vitro* diagnostic procedures.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions.

The *artus* SARS-CoV-2 Prep&Amp UM Kit is intended to be used with the Rotor-Gene Q MDx System, ABI 7500 Fast Dx, QuantStudio 5 Dx, cobas z 480 or CFX96 Dx as real-time PCR systems.

# Description and Principle

## Pathogen information

Coronaviruses, a genus in the family *Coronaviridae*, are large enveloped, positive-stranded RNA viruses that cause highly virulent disease in humans and domestic animals (1). Coronaviruses are known to infect humans account for one-third of common cold infections and are also a well-known cause of nosocomial upper respiratory infections in premature infants (2).

A novel member of the coronavirus family caused an outbreak of the respiratory disease in Wuhan City in China (1, 3). First named novel coronavirus (2019-nCoV), SARS-CoV-2 differs from SARS-CoV (1, 3), which was responsible for the 2003 outbreak, and MERS-CoV, which has been circulating in the Middle East since 2012. SARS-CoV-2 is the causative agent of COVID-19. SARS-CoV-2 RNA is detectable during the early and acute phases of the infection from various upper respiratory tract specimens (nasal, oropharyngeal, and nasopharyngeal swabs) and in neat saliva specimens (3).

Combined with patient history and SARS-CoV-2 epidemiology, real-time RT-PCR assays have become the gold standard for SARS-CoV-2 diagnosis. The European Centre for Disease Prevention and Control (ECDC) has proposed to combine real-time RT-PCR-based assays with immunoassays to monitor infection status and to evaluate the efficiency of the restrictive measures taken to control the outbreak (4, 5).

The *artus* SARS-CoV-2 Prep&Amp UM Kit is designed to cover 2 targets (N1 and N2) of the N gene detected with the same fluorescence channel. The two targets are not differentiated, and amplification of either or both targets leads to a fluorescence signal. Positive results are indicative of the presence of SARS-CoV-2 but do not rule out co-infection with other pathogens. On the other hand, negative real-time RT-PCR results do not exclude a possible infection.

## Summary and explanation

The *artus* SARS-CoV-2 Prep&Amp UM Kit constitutes a ready-to-use system with a simple sample preparation step followed by detection of the SARS-CoV-2 RNA using real-time RT-PCR on the RGQ MDx system, ABI 7500 Fast Dx, CFX96 Dx, cobas z 480, or QuantStudio 5 Dx (Figure 1).

The SARS-CoV-2 UM Amp Buffer contains reagents and enzymes for the specific amplification of a 72 base pair (bp) and a 67 bp region of the SARS-CoV-2 RNA genome and for their direct detection in the “Green” fluorescence channel of the RGQ MDx instruments and in the “FAM” fluorescence channel of the ABI 7500 Fast Dx, CFX96 Dx, cobas z 480, or QuantStudio 5 Dx.


The Primers and Probes Mix of the *artus* SARS-CoV-2 Prep&Amp UM Kit also contains the oligonucleotides required for the RNase P amplifications. When detected in the “Yellow” fluorescence channel of the RGQ MDx instrument, in the VIC/HEX of ABI 7500 Fast Dx, CFX96 Dx, cobas z 480, or QuantStudio 5 Dx, those amplifications assure that enough biological sample has been collected. This control is critical to ensure the presence of biological samples in SARS-CoV-2 negative samples. An amplification should always be detectable; otherwise, it questions the sample quality.

The *artus* SARS-CoV-2 Prep&Amp UM Kit also contains a third heterologous amplification system to reveal possible real-time RT-PCR inhibition. This is detected as an internal RNA control (IC) in the “Red” fluorescence channel of the RGQ MDx instruments or in the Cy5/ATTO647N of ABI 7500 Fast Dx, CFX96 Dx, cobas z 480, or QuantStudio 5 Dx. Because the IC is included in the SARS-CoV-2 Amp Primers Mix, its amplification should be constant unless a real-time RT-PCR inhibitor is present in the sample or in the PCR reaction, which delays or prevents amplification.

External positive and negative controls (SARS-CoV-2 Positive Control and nuclease-free water used as NTC, respectively) are supplied in the *artus* SARS-CoV-2 Prep&Amp UM Kit to attest

of the performance of the PCR step. A no extraction control (SARS-CoV-2 UM Prep Buffer used as NEC) is strongly recommended to verify the absence of real-time RT-PCR inhibitors in the preparation buffer.

Taken together, the efficiency of the reverse transcription and the PCR steps are monitored by these controls.



(Continued on next page)

(continued from previous page)




Figure 1. *artus* SARS-CoV-2 Prep&Amp UM Kit workflow

# Materials Provided

## Kit contents

### *artus* SARS-CoV-2 Prep&Amp UM Kit

Catalog no.			4511460	4511469	
Number of reactions			768	3072	
Tube color	Lid Color	Identity	Tube ID	Volume (µl)	Volume (µl)
Clear	Yellow	SARS-CoV-2 UM Prep Buffer	Preparation Buffer	2 x 930	8 x 930
Clear	Blue	SARS-CoV-2 UM Amp Buffer	Master Mix	4 x 1440	16 x 1440
Clear	Purple	SARS-CoV-2 Amp Primers	Primers and Probes	4 x 1680	16 x 1680
Clear	Green	SARS-CoV-2 Internal Control	Internal Control (IC)	1 x 1390	4 x 1390
Clear	Red	SARS-CoV-2 Positive Control	Positive Control	1 x 220	4 x 220
Clear	Clear	Water for NTC	Water (NTC)	1 x 1900	4 x 1900
Clear	Clear	ROX Reference Dye	ROX Dye	1 x 210	4 x 210

## Kit components

### Reagents

In each tube, the reagent volumes have been optimized for 8 batches of 96 samples (for the 768 reactions kit) or 32 batches of 96 reactions (for the 3072 reactions kit), including a positive control (PC), a no template control (NTC), and a no extraction control (NEC).

Fewer or a greater number of samples may be run, but there will be sub-optimal reagent usage. It is recommended to avoid multiple freeze–thaw cycles. Reagents may be aliquoted to avoid multiple freeze–thaw cycles.

## Primers and probes

Primers and probes targeting the SARS-CoV-2 sequences are based on the primers and probes designed by the Centers for Disease Control and Prevention (CDC).

## Controls and calibrators

The assay contains 5 controls to monitor the real-time RT-PCR efficiency.

**Internal control (IC):** The internal control is a single-strand IVT RNA that verifies the presence of contaminants that could inhibit the reverse transcription. The internal control also monitors the reverse transcription efficiency in the no template control (NTC) and in the no extraction control (NEC).

**No template control (NTC):** The no template control is composed of nuclease-free water. It is added to the PCR plate to verify introduction of contaminants during the PCR plate preparation that could lead to misinterpretation of the SARS-CoV-2 targets.

**Positive control (PC):** The positive control is a double-strand DNA amplified with the SARS-CoV-2 Primers and Probes (P&P mix). Its detection verifies the efficiency of the reagent involved in the PCR amplification step.

**No extraction control (NEC):** The no extraction control is composed of the SARS-CoV-2 UM Prep Buffer. It is processed in parallel with the clinical samples to verify introduction of contaminants during the sample preparation that could lead to misinterpretation of the SARS-CoV-2 targets.

**Sampling Control:** The Sampling Control detects the RNase P gene and is critical to ensure the presence of biological samples in SARS-CoV-2 negative samples. Amplification of the sampling control should always be detectable; otherwise, it questions the sample quality.

## Platforms and software

Prior to use, ensure that instruments have been maintained and calibrated according to the manufacturer's recommendations. This kit can be used in five workflows that require the use of the following real-time RT-PCR instruments and their appropriate software:

- Rotor-Gene Q MDx 5plex HRM: Rotor-Gene Q software version 2.3.1 or higher
- ABI 7500 Fast Dx: SDS software version 1.4.1 or higher
- CFX96 Dx with CFX Manager Dx Software version 3.1.3090.1022 or higher
- cobas z 480 with LightCycler® 480 SW UDF version 2.0.0 or higher
- QuantStudio 5 Dx with QuantStudio 5 Dx IVD Software version 1.0.1 or higher and QuantStudio 5 Dx TD software version 1.0.1 or higher

# Materials Required but Not Provided

## Consumables and Equipment

### Common consumables and equipment

- Desktop centrifuge with rotor for 2 ml reaction tubes
- Pipettes (adjustable)
- Vortex mixer
- Block heater
- Disposable powder-free gloves
- Sterile and nuclease-free pipette tips with filters
- 1.5 ml or 2 ml PCR-free tubes
- 96-well plate centrifuge instrument

### Consumables and equipment for each platform

#### **Rotor-Gene Q MDx 5plex HRM Instrument**

- 0.1 ml PCR tubes, for use with the Rotor-Gene Q MDx (Strip Tubes and Caps, 0.1 ml, cat. no. 981103).
- 72-Well Rotor (cat.no. 9018903) and Locking Ring 72-Well Rotor (cat. no. 9018904)

#### **ABI 7500 Fast Dx Instrument**

- 96-Well MicroAmp™ (Thermo Fisher Scientific, cat. no. N8010560)
- MicroAmp Optical Adhesive film (Thermo Fisher Scientific, cat. no. 4360954)

#### **CFX96 Dx Instrument**

- Hard-Shell® 96-Well PCR Plate, low profile, thin wall, skirted white/clear (Bio-Rad Laboratories Inc., cat. no. HSP9601)
- Microseal 'B' PCR Plate Sealing Film, Adhesive, Optical (Bio-Rad Laboratories Inc., cat. no. MSB1001).

### **cobas z 480 Instrument**

- LightCycler 480 Multiwell Plate, white (Roche Group, cat. no. 04729692001).
- LightCycler 480 Sealing Foil (Roche Group, cat. no. 04729757001).

### **QuantStudio 5 Dx Instrument**

- MicroAmp EnduraPlate™ Optical 96-Well Clear Reaction Plate (Thermo Fisher Scientific, cat. no. A36924)
- MicroAmp Optical Adhesive film (Thermo Fisher Scientific, cat. no. 4360954)

# Warnings and Precautions

Please be aware that you may be required to consult your local regulations for reporting serious incidents that have occurred in relation to the device to the manufacturer and the regulatory authority in which the user and/or the patient is established.

## Safety information

When working with chemicals, always wear a suitable lab coat, disposable gloves, and protective goggles. For more information, please consult the appropriate safety data sheets (SDSs). These are available online in a convenient and compact PDF format at [www.qiagen.com/safety](http://www.qiagen.com/safety), where you can find, view, and print the SDS for each QIAGEN kit and kit component.

Always wear appropriate personal protective equipment, including but not limited to disposable powder-free gloves, a lab coat, and protective eyewear. Protect skin, eyes, and mucus membranes. Change gloves often when handling samples.

All samples should be treated as potentially hazardous. Always observe safety precautions as outlined in relevant guidelines, such as the Clinical and Laboratory Standards Institute® (CLSI) *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline* (M29), or other appropriate documents.

Specimens and samples are potentially infectious. Discard sample and assay waste according to your local safety procedures.

## Precautions

- Observe standard laboratory procedures for keeping the working area clean and contamination-free. Dedicate an area with specific equipment to manipulate RNA.
- Follow good laboratory practices to minimize cross-contamination.
- Pay attention to avoid contamination with RNase during the experiment and use RNase-free plasticware.
- Make sure to have a good traceability with records, especially for sample identification.

# Reagent Storage and Handling

Attention should be paid to expiration dates and storage conditions printed on the box and all components' labels. Do not use expired or incorrectly stored components.

The *artus* SARS-CoV-2 Prep&Amp UM Kit can be kept at  $-30^{\circ}\text{C}$  to  $-15^{\circ}\text{C}$  until expiry date.

# Specimen Transport, Storage, and Handling

The *artus* SARS-CoV-2 Prep&Amp UM Kit is for use with nasopharyngeal, nasal, and oropharyngeal swabs and neat saliva specimens. All samples should be treated as potentially hazardous. The Centers for Disease Control and Prevention (CDC) and Public Health England have provided guidelines for sample collection, handling, and testing clinical specimens. Refer to these guidelines or to other relevant national reference laboratory protocols for additional information.

## Nasopharyngeal, nasal and oropharyngeal swabs collection, transport and storage

For swab collection, storage, and transport, please refer to the supplier's recommendations. Swabs must be fully immersed in transport media to maintain specimen integrity. Nasopharyngeal swab samples remain stable and can be stored at:

- $4^{\circ}\text{C}$  (2 to  $8^{\circ}\text{C}$ ) for up to 72 hours
- $-70^{\circ}\text{C}$  for 2 weeks

Nasopharyngeal swab samples remain stable through 3 freeze–thaw cycles.

## Neat saliva sample collection, transport and storage

Neat saliva samples must be collected into sterile containers without any preservatives, buffers, or other additives.

Instructions for neat saliva collection:

- Avoid coughing prior to neat saliva collection.
- Do not eat, drink, smoke or vape, chew gum, or brush teeth 30 minutes before neat saliva collection.
- No dental work or dental examination should be performed 24 hours before neat saliva collection.

The neat saliva samples remain stable and can be stored at:

- Room temperature (18–26°C) for up 72 hours
- 4°C (2 to 8°C) for up to 72 hours
- A combined storage at RT then 4°C then –20°C(–30 to –15°C) up to 12 days
- –20°C (–30 to –15°C) for 1 month

Neat saliva samples remain stable through 3 freeze–thaw cycles.

If sample storage conditions are deviating from this guidance, please validate your own storage conditions.

# Protocol: Sample preparation and SARS-CoV-2 Detection on the RGQ MDx 5plex HRM

This protocol describes the sample and the real-time RT-PCR preparation to detect the SARS-CoV-2 targets in human nasal, nasopharyngeal, or oropharyngeal swabs stored in transport media and in neat saliva samples on the RGQ MDx 5plex HRM real-time RT-PCR instrument associated with the Rotor-Gene Q software version 2.3.1.49 (or higher).

## Important points before starting

- Verify that the expiration dates and storage conditions printed on the box and all component labels are followed. Do not use expired or incorrectly stored components.
- Use well-maintained and calibrated equipment.
- Pay attention to avoid contamination with RNases during the experiment and use nuclease-free plasticware.

## Things to do before starting

- Respiratory samples may be kept at room temperature (15–25°C) during preparation steps and reaction setup, but it is recommended to keep them on ice or at 4°C on a cooling rack.
- Saliva samples may be kept on ice or at 4°C on a cooling rack but it is recommended to keep them at room temperature (15–25°C) during preparation steps and reaction setup.
- Before use, let the SARS-CoV-2 UM Prep Buffer, SARS-CoV-2 UM Amp Buffer, SARS-CoV-2 Amp Primers, SARS-CoV-2 IC, Water for NTC, and SARS-CoV-2 Positive Control completely thaw at room temperature. Keep tubes at room temperature and protected from light until use.
- Before use, homogenize the SARS-CoV-2 UM Prep Buffer and the SARS-CoV-2 UM Amp Buffer by inverting them 2-3 times (do not vortex), followed by a quick spin. All the other individual reagents can be homogenized by pulse vortexing for 3-5 seconds or by inverting 2-3 times, followed by a quick spin.

- The SARS-CoV-2 UM Prep Buffer inhibits RNases present in the clinical samples for the detection step, but it is not a virus-inactivating solution. All samples should be treated as potentially hazardous.
- Verify that the cycling conditions of the real-time RT-PCR platform are as specified in this protocol.
- Reagents may be aliquoted to avoid multiple freeze–thaw cycles.
- Freshly prepare the reaction mix (<2 h to the RT-PCR plate launch).
- To minimize contamination, the sample and the RT-PCR preparations should be done in distinct zones.

## Procedure

**Sample preparation:** For respiratory tract specimens (nasal, oropharyngeal, and nasopharyngeal swabs), , follow Step 1. For saliva specimens proceed to Step 2.

1. Respiratory tract specimens (nasal, oropharyngeal, and nasopharyngeal swabs):
  - 1a. Vortex the swab containing the sample vigorously.
  - 1b. Aliquot 50-200 µl of sample into 1.5mL PCR-free tubes
  - 1c. Perform heating step at 70°C for 10 min on a block heater. Cool down the samples on ice for at least 5 min. then, keep the samples on ice or at 4°C.
2. Saliva samples:
  - 2a. Liquefaction(to facilitate pipetting): heat saliva sample at 95°C for 15 min (unspecified volume, container, or heating device).
  - 2b. Homogenize sample by gently pipetting up and down 8–10 times.
  - 2c. Aliquot 50 µl of the sample into a 1.5 ml PCR-free tube.
  - 2d. Perform heating step at 95°C for 15 min on a block heater, then keep the sample at room temperature for at least 5 min until loading into PCR well or tube.
3. At first use, complete the SARS-CoV-2 UM Amp Buffer with the ROX reference dye.
  - 3a. Add 32.8 µl of the ROX dye to 1 tube of SARS-CoV-2 UM Amp Buffer.
  - 3b. Close the lid containing the SARS-CoV-2 UM Amp Buffer and the ROX dye and invert the tube 3 times.
  - 3c. Spin down the SARS-CoV-2 UM Amp Buffer containing ROX dye at the bottom of the tube.

4. For a full RGG MDx plate (72 wells), prepare an aliquot mix of the SARS-CoV-2 Amp Primers with the SARS-CoV-2 Internal Control.
  - 4a. Transfer the required volumes of the SARS-CoV-2 Amp Primers and the SARS-CoV-2 Internal Control according to Table 1 into a new 1.5 mL PCR-free tube.
  - 4b. Close the lid and invert the tube 3 times or pulse vortex the tube for 3-5 s.
  - 4c. Spin down the SARS-CoV-2 Amp Primers containing the IC at the bottom of the tube.

**Table 1. SARS-CoV-2 Amp Primers + IC mix setup**

Reagents	Stock concentration	Final concentration	Number of reactions Volume (µl)	
			1 rxn	72 rxns (+20% extra volume*)
SARS-CoV-2 Amp Primers	<b>3.45x</b>	1x	7.25	626.4
SARS-CoV-2 Internal Control	166.67 cp/µl	10 cp/µl	1.5	129.6
Total SARS-CoV-2 Amp Primers + IC mix			8.75	756

\* **Note:** Adjust the volumes of SARS-CoV-2 Amp Primers and SARS-CoV-2 Internal Control according to the number of samples to be tested. Consider extra volume to compensate for the dead volume.

5. Prepare a reaction mix according to Table 2 and mix thoroughly by inverting the tube 3 times.

**Table 2. Reaction mix setup**

Reagents	Stock concentration	Final concentration	Number of reactions Volume (µl)	
			1 rxn	72 rxns (+20% extra volume*)
SARS-CoV-2 UM Amp Buffer +ROX mix	4x	1x	6.25	540
SARS-CoV-2 Amp Primers + IC mix	<b>2.9x</b>	1x	8.75	756
Total reaction volume		–	15.00	1296


\* **Note:** Adjust the volumes of SARS-CoV-2 Amp Buffer and SARS-CoV-2 Amp Primers according to the number of samples to be tested. Consider extra volume to compensate for the dead volume.

6. Dispense 8 µl of nuclease-free water to the PCR tube assigned to the NEC.

7. Load 10 µl of nuclease-free water into the PCR tube assigned to the NTC.
8. Dispense 2 µl of SARS-CoV-2 UM Prep Buffer into each PCR tube assigned to the NEC and the prepared samples.
9. Add 8 µl of the prepared sample to a PCR tube containing the SARS-CoV-2 UM Prep Buffer. Mix by pipetting up and down 5 times.
10. Add 15 µl of the reaction mix prepared in Step 5 to the tubes dedicated to samples and controls (Figure 2 provided as an example). Mix by pipetting up and down 5 times, then close the PCR tube lids, except for the one reserved as the SARS-CoV-2 Positive Control.  
**Note:** Verify that tubes are well closed to prevent cross-contamination.
11. Load 10 µl of the SARS-CoV-2 Positive Control into the appropriate PCR tube. Mix by pipetting up and down 5 times.
12. Set the RT-PCR program of the RGQ MDx 5plex HRM according to specifications in Table 3.  
**Note:** Data acquisition should be performed during the annealing/extension step.
13. Place tubes in the real-time cycler (an example of tube layout is represented in Figure 2), and start the cycling program as described in Table 3.  
**Note:** Be careful to follow the same tube position and order between the assay set-up and the real-time cycler steps.

**Table 3. SARS-CoV-2 Prep&Amp UM program**

Steps	Time	Temperature (°C)	Number of cycles	Acquisition
Reverse transcription	10 min	50	1	No
PCR initial heat activation	2 min	95	1	No
2-step cycling				
Denaturation	5 s	95	40	No
Annealing/Extension	30 s	58		Green , Yellow and Red



- 1: PC
- 2: NTC
- 3: NEC
- 4: Sample 1
- 5: Sample 2
- 6: Sample 3
- 7: ...

**Figure 2. Example of tube layout on the RGQ MDx 5plex HRM platform**

14. Click Gain optimization in the “New Run Wizard” and open Auto-gain Optimization Setup.
15. Verify that the acquisition channels are set as described in Table 4.

**Table 4. RGQ MDx 5plex HRM configuration**

Name	PC tube position	Min reading (FI)	Max reading (FI)	Min gain	Max gain
Green	1*	5 FI	10 FI	-10	10
Yellow	1*	5 FI	10 FI	-10	10
Red	1*	5 FI	10 FI	-10	10

\* **Note:** This needs to be changed according to the SARS-CoV-2 Positive Control tube position.

16. Select Perform optimization before the first acquisition.
17. Start the run.
18. At the end of the run, analyze results (see the Results section).

# Protocol: Sample Preparation and SARS-CoV-2 Detection on ABI 7500 Fast Dx

This protocol is for preparing and detecting SARS-CoV-2 targets in human nasal, nasopharyngeal, or oropharyngeal swabs stored in transport media and in neat saliva samples on the ABI 7500 Fast Dx real-time RT-PCR instrument.

## Important points before starting

- Verify that the expiration dates and storage conditions printed on the box and all component labels are followed. Do not use expired or incorrectly stored components.
- Use well-maintained and calibrated equipment.
- Pay attention to avoid contamination with RNases during the experiment, and use nuclease-free plasticware.
- When using ABI 7500 Fast Dx, ROX Dye must be added to the master mix tube before first use.

## Things to do before starting

- Respiratory samples may be kept at room temperature (15–25°C) during preparation steps and reaction setup, but it is recommended to keep them on ice or at 4°C on a cooling rack.
- Saliva samples may be kept on ice or at 4°C on a cooling rack but it is recommended to keep them at room temperature (15–25°C) during preparation steps and reaction setup.
- The ROX dye is required when using the ABI 7500 Fast Dx.
- Data must be acquired with the ROX passive dye setting.
- Before use, let the SARS-CoV-2 UM Prep Buffer, SARS-CoV-2 UM Amp Buffer, SARS-CoV-2 Amp Primers, SARS-CoV-2 IC, Water for NTC, and SARS-CoV-2 Positive Control completely thaw at room temperature. Keep tubes at room temperature and protected from light until use.

- Before use, homogenize the SARS-CoV-2 UM Prep Buffer and the SARS-CoV-2 UM Amp Buffer by inverting 2-3 times (do not vortex), followed by a quick spin. All the other individual reagents can be homogenized by pulse vortexing for 3-5 seconds or by inverting 2-3 times, followed by a quick spin.
- The SARS-CoV-2 UM Prep Buffer inhibits RNases present in the clinical samples for the detection step but is not a virus-inactivating solution. All samples should be treated as potentially hazardous.
- Verify that the cycling conditions of the real-time RT-PCR platform are as specified in this protocol.
- Reagents may be aliquoted to avoid multiple freeze–thaw cycles.
- Freshly prepare the reaction mix (<2 h to the RT-PCR plate launch).
- To minimize contamination, the sample and the RT-PCR preparations should be done in distinct zones.

## Procedure

**Sample preparation:** For respiratory tract specimens (nasal, oropharyngeal, and nasopharyngeal swabs), follow Step 1. For saliva specimens proceed to Step 2.

1. Respiratory tract specimens (nasal, oropharyngeal, and nasopharyngeal swabs):
  - 1a. Vortex the swab containing sample vigorously.
  - 1b. Aliquot 50-200  $\mu$ l of sample into 1.5mL PCR-free tubes.
  - 1c. Perform heating step at 70°C for 10 min on a block heater.
  - 1d. Cool down samples on ice for at least 5 min, then keep the samples on ice or at 4°C.
2. Saliva samples:
  - 2a. Liquefaction (to facilitate pipetting): heat saliva sample at 95°C for 15 min (unspecified volume, container, or heating device).
  - 2b. Homogenize sample by gently pipetting up and down 8–10 times
  - 2c. Aliquot 50  $\mu$ l of the sample into a 1.5 ml PCR-free tube.
  - 2d. Perform heating step at 95°C for 15 min on a block heater, then keep the sample at room temperature for at least 5 min until their loading into PCR well or tube.

3. At first use, complete the SARS-CoV-2 UM Amp Buffer with the ROX Reference Dye.
  - 3a. Add 32.8  $\mu\text{l}$  of the ROX Dye to a tube of SARS-CoV-2 UM Amp Buffer.
  - 3b. Close the lid containing the SARS-CoV-2 UM Amp Buffer and the ROX Dye and invert the tube 3 times.
  - 3c. Spin down the SARS-CoV-2 UM Amp Buffer containing ROX Dye at the bottom of the tube.
4. For a full ABI 7500 Fast Dx plate (96 wells), prepare an aliquot mix of the SARS-CoV-2 Amp Primers with the SARS-CoV-2 Internal Control.
  - 4a. Transfer the required volume of the SARS-CoV-2 Amp Primers and the SARS-CoV-2 Internal Control according to Table 5 into a new 1.5 mL PCR-free tube.
  - 4b. Close the lid and invert the tube 3 times or pulse vortex the tube for 3-5 s.
  - 4c. Spin down the SARS-CoV-2 Amp Primers containing the IC to bring the solution to the bottom of the tube.

**Table 5. SARS-CoV-2 Amp Primers + IC mix setup**

SARS-CoV-2 Amp Primers + IC mix	Number of reactions			
	Volume ( $\mu\text{l}$ )			
Reagents	Stock concentration	Final concentration	1 rxn	96 rxns (+ 20% extra volume*)
SARS-CoV-2 Amp Primers	3.45x	1x	7.25	835.2
SARS-CoV-2 Internal Control	166.67 cp/ $\mu\text{l}$	10 cp/ $\mu\text{l}$	1.5	172.8
Total SARS-CoV-2 Amp Primers + IC mix			8.75	1008

\* **Note:** Adjust the volumes of SARS-CoV-2 Amp Primers and SARS-CoV-2 Internal Control according to the number of samples to be tested. Consider extra volume to compensate for the dead volume.

5. Prepare a reaction mix according to Table 6 and mix thoroughly by inverting the tube 3 times.

**Table 6. Reaction mix setup**

Reagents	Stock concentration	Final concentration	Number of reactions Volume (µl)	
			1 rxn	96 rxns (+20% extra volume*)
SARS-CoV-2 UM Amp Buffer + ROX mix	4x	1x	6.25	720
SARS-CoV-2 Amp Primers + IC mix	<b>2.9x</b>	1x	8.75	1008
Total reaction volume		–	15.00	1728

\* **Note:** Adjust the volume of SARS-CoV-2 UM Amp Buffer and SARS-CoV-2 Amp Primers according to the number of samples to test. Consider extra volume to compensate for the dead volume.

6. Dispense 8 µl of nuclease-free water to the well assigned to the NEC.
7. Load 10 µl of nuclease-free water into the well assigned to the NTC.
8. Dispense 2 µl of SARS-CoV-2 UM Prep Buffer into each well assigned to the NEC and to the prepared samples.
9. Add 8 µl of the prepared sample to a well containing the SARS-CoV-2 UM Prep Buffer. Mix by pipetting up and down 5 times.
10. Add 15 µl of the reaction mix prepared in Step 5 to the wells dedicated to samples and controls (see example on Figure 3). Mix by pipetting up and down 5 times.
11. Load 10 µl of the SARS-CoV-2 Positive Control into the appropriate well. Mix by pipetting up and down 5 times.
12. Seal the PCR plate well to prevent cross-contamination. Make sure to apply pressure uniformly across the entire plate to obtain a tight seal across individual wells.
13. Centrifuge the PCR plate briefly to collect liquid at the bottom of the well.
14. Set the real-time RT-PCR program on the “Standard 7500” Run Mode of the ABI 7500 Fast Dx according to Table 7.

**Note:** After clicking on **file** and **new**, verify that the assay is **Standard Curve (Absolute Quantitation)**, and Run Mode is set to **Standard 7500**. Select the FAM, VIC, and Cy5 as reporters with Quencher set to **None**, and data must be acquired with the **ROX** as **passive reference**.

**Note:** Data acquisition should be performed during the annealing/extension step.

**Note:** Please refer to the *ABI 7500 Fast Dx Instructions for Use* for more details.

15. Place the plate in the real-time cycler (an example of a PCR plate layout is represented in Figure 3 and start the cycling program as described in Table 7.
16. Select the used wells and apply the FAM, VIC, and Cy5 reporters. Data must be acquired with the ROX passive dye **ON**.
17. Verify that the Standard Curve of the ABI 7500 Fast Dx is configured to Absolute Quantitation.
18. Start the run.
19. At the end of the run, analyze results (see the Results section).

**Table 7. SARS-CoV-2 Prep&Amp UM program**

Steps	Time	Temperature (°C)	Number of cycles	Acquisition
Reverse transcription	10 min	50	1	No
PCR initial heat activation	2 min	95	1	No
2-step cycling				
Denaturation	5 s	95	40	No
Annealing/Extension	30 s	58		FAM, VIC, and Cy5

	1	2	3	4	5	6	7	8	9	10	11	12
A	PC											
B	NTC											
C	NEC											
D	Sample 1											
E	Sample 2											
F	Sample 3											
G	...											
H												

**Figure 3. Example of plate layout on ABI 7500 Fast Dx**

# Protocol: Sample Preparation and SARS-CoV-2 Detection on the CFX96 Dx

This protocol is for preparing and detecting SARS-CoV-2 targets in human nasal, nasopharyngeal, oropharyngeal swabs stored in transport media and in neat saliva samples on the CFX96 Dx (Bio-Rad Laboratories Inc., cat. no.1845097-IVD.(optical reaction module) and 1841000-IVD (Thermal Cycler module) with CFX Manager Dx Software version 3.1.309001022 or higher.

## Important points before starting

- Verify that the expiration dates and storage conditions printed on the box and all component labels are followed. Do not use expired or incorrectly stored components.
- Use well-maintained and calibrated equipment.
- Pay attention to avoid contamination with RNases during the experiment and use nuclease-free plasticware.

## Things to do before starting

- Respiratory samples may be kept at room temperature (15–25°C) during preparation steps and reaction setup, but it is recommended to keep them on ice or at 4°C on a cooling rack.
- Saliva samples may be kept on ice or at 4°C on a cooling rack but it is recommended to keep them at room temperature (15–25°C) during preparation steps and reaction setup.
- Before use, let the SARS-CoV-2 UM Prep Buffer, SARS-CoV-2 UM Amp Buffer, SARS-CoV-2 Amp Primers, SARS-CoV-2 IC, Water for NTC, and SARS-CoV-2 Positive Control completely thaw at room temperature. Keep tubes at room temperature and protected from light until use.

- Before use, homogenize the SARS-CoV-2 UM Prep Buffer and the SARS-CoV-2 UM Amp Buffer by inverting them 2-3 times (do not vortex), followed by a quick spin. All the other individual reagents can be homogenized by pulse vortexing for 3-5 seconds or by inverting 2-3 times, followed by a quick spin.
- The SARS-CoV-2 UM Prep Buffer inhibits RNases present in the clinical samples for the detection step, but it is not a virus-inactivating solution. All samples should be treated as potentially hazardous.
- Verify that the cycling conditions of the real-time RT-PCR platform are as specified in this protocol.
- Reagents may be aliquoted to avoid multiple freeze–thaw cycles.
- Freshly prepare the reaction mix (<2 h to PCR plate launch).
- To minimize contamination, the sample and the real-time RT-PCR preparations should be done in distinct zones.

## Procedure:

**Sample preparation:** For respiratory tract specimens (nasal, oropharyngeal, and nasopharyngeal swabs, follow Step 1. For saliva specimens proceed to Step 2.

1. Respiratory tract specimens (nasal, oropharyngeal, and nasopharyngeal swabs):
  - 1a. Vortex the swab containing the sample vigorously
  - 1b. Aliquot 50-200 µl of the sample into 1.5mL PCR-free tubes
  - 1c. Perform heating step at 70°C for 10 min on a block heater.
  - 1d. Cool down the samples on ice for at least 5 min, then, keep the samples on ice or at 4°C.
2. Saliva samples:
  - 2a. Liquefaction (to facilitate pipetting): heat saliva sample at 95°C for 15 min (unspecified volume, container, or heating device).
  - 2b. Homogenize sample by gently pipetting up and down 8–10 times.
  - 2c. Aliquot 50 µl of the sample into a 1.5 ml PCR-free tube.
  - 2d. Perform heating step at 95°C for 15 min on a block heater. Then, keep the sample at room temperature for at least 5 min until loading into PCR well or tube.

3. At first use, complete the SARS-CoV-2 UM Amp Buffer with the ROX reference dye.
  - 3a. Add 32.8  $\mu\text{l}$  of the ROX dye to 1 tube of SARS-CoV-2 UM Amp Buffer.
  - 3b. Close the lid containing the SARS-CoV-2 UM Amp Buffer and the ROX dye and invert the tube 3 times.
  - 3c. Spin down the SARS-CoV-2 UM Amp Buffer containing ROX dye at the bottom of the tube.
4. For a full CFX96 Dx plate (96 wells), prepare an aliquot mix of the SARS-CoV-2 Amp Primers with the SARS-CoV-2 Internal Control.
  - 4a. Transfer the required volume of the SARS-CoV-2 Amp Primers and the SARS-CoV-2 Internal Control according to Table 8 into a new 1.5 mL PCR-free tube.
  - 4b. Close the lid and invert the tube 3 times or pulse vortex the tube for 3-5 s.
  - 4c. Spin down the SARS-CoV-2 Amp Primers containing the IC to bring the solution to the bottom of the tube.

**Table 8. SARS-CoV-2 Amp Primers + IC mix setup**

Reagents	Stock concentration	Final concentration	Number of reactions Volume ( $\mu\text{l}$ )	
			1 rxn	96 rxns (+ 20% extra volume*)
SARS-CoV-2 Amp Primers	3.45x	1x	7.25	835.2
SARS-CoV-2 Internal Control	166.67 cp/ $\mu\text{l}$	10 cp/ $\mu\text{l}$	1.5	172.8
Total SARS-CoV-2 Amp Primers + IC mix			8.75	1008

\* **Note:** Adjust the volumes of SARS-CoV-2 Amp Primers and SARS-CoV-2 Internal Control according to the number of samples to test. Consider extra volume to compensate for the dead volume.

5. Prepare a reaction mix according to Table 9 and mix thoroughly by inverting the tube 3 times.

**Table 9. Reaction mix setup**

Reagents	RT-PCR reaction mix		Number of reactions Volume (µl)	
	Stock concentration	Final concentration	1 rxn	96 rxns (+20% extra volume*)
SARS-CoV-2 UM Amp Buffer + ROX mix	4x	1x	6.25	720
SARS-CoV-2 Amp Primers + IC mix	<b>2.9x</b>	1x	8.75	1008
Total reaction volume		–	15.00	1728

\* **Note:** Adjust the volumes of SARS-CoV-2 UM Amp Buffer and SARS-CoV-2 Amp Primers according to the number of samples to test. Consider extra volume to compensate for the dead volume.

6. Dispense 8 µl of nuclease-free water to the well assigned to the NEC.
7. Load 10 µl of nuclease-free water into the well assigned to the NTC.
8. Dispense 2 µl of SARS-CoV-2 UM Prep Buffer into each well assigned to the NEC and the prepared samples.
9. Add 8 µl of the prepared sample to a well containing the SARS-CoV-2 UM Prep Buffer. Mix by pipetting up and down 5 times.
10. Add 15 µl of the reaction mix prepared in Step 5 to the wells dedicated to samples and controls (Figure 4 provided as an example). Mix by pipetting up and down 5 times.
11. Load 10 µl of the SARS-CoV-2 Positive Control into the appropriate well. Mix by pipetting up and down 5 times.
12. Seal the PCR plate well to prevent cross-contamination. Make sure to apply pressure uniformly across the entire plate to obtain a tight seal across individual wells.
13. Centrifuge the PCR plate briefly to collect liquid at the bottom of the well.
14. On the CFX Manager Dx Software > Startup Wizard, under the run type, select user defined.
15. **Protocol** tab: Set the real-time RT-PCR program according to Table 10 for 25 µl of reaction volume.

**Note:** In the **Protocol Editor** window, click on the **Step Options** button to adjust the ramp rate at 1.6°C/sec in each of the 4 steps of the RT-PCR program.

**Note:** Data acquisition should be performed during the annealing/extension step.

**Note:** Please refer to the *CFX96 Dx Instruction for Use* for more details.

16. **Plate** tab: Select the used wells and apply the FAM, HEX, and Cy5 reporters.
17. Place the plate in the real-time cycler (an example of a PCR plate layout is represented in Figure 4).
18. **Start Run** tab: click on Start the run.
19. At the end of the run, analyze the results (see the Results section).

**Table 10. SARS-CoV-2 Prep&Amp UM program for the CFX96 Dx**

Steps	Time	Temperature (°C)	Ramp Rate (°C/sec)	Number of repetitions	Acquisition
1. Reverse transcription	10 min	50	1.6	1	No
2. PCR initial heat activation	2 min	95	1.6	1	No
2-step cycling				39*	
Denaturation	5 s	95	1.6	1	No
Annealing/Extension	30 s	58	1.6	1	FAM, HEX, and Cy5

\*The CFX works by repetition. For the program to run 40 cycles, 39 repetitions must be set for the two steps cycling (as Step 5 "GOTO" on the software).

	1	2	3	4	5	6	7	8	9	10	11	12
A	PC											
B	NTC											
C	NEC											
D	Sample 1											
E	Sample 2											
F	Sample 3											
G	...											
H												

**Figure 4. Example of plate layout on CFX96 Dx**

# Protocol: Sample Preparation and SARS-CoV-2 Detection on the cobas z 480

This protocol describes the sample and the real-time RT-PCR preparation to detect the SARS-CoV-2 targets in human nasal, nasopharyngeal, oropharyngeal swabs stored in transport media and in neat saliva sample on the cobas z 480 with LightCycler 480 SW UDF version 2.0.0 (or higher).

## Important points before starting.

- Verify that the expiration dates and storage conditions printed on the box and all component labels are followed. Do not use expired or incorrectly stored components.
- Use well-maintained and calibrated equipment.
- Pay attention to avoid contamination with RNases during the experiment and use nuclease-free plasticware.

## Things to do before starting.

- Respiratory samples may be kept at room temperature during preparation steps and reaction setup, but it is recommended to keep them on ice or at 4°C on a cooling rack.
- Saliva samples may be kept on ice or at 4°C on a cooling rack but it is recommended to keep them at room temperature (15–25°C) during preparation steps and reaction setup.
- Before use, let the SARS-CoV-2 UM Prep Buffer, SARS-CoV-2 UM Amp Buffer, SARS-CoV-2 Amp Primers, SARS-CoV-2 IC, Water for NTC, and SARS-CoV-2 Positive Control completely thaw at room temperature (15–25°C). Keep tubes at room temperature and protected from light until use.
- Before use, homogenize the SARS-CoV-2 UM Prep Buffer and the SARS-CoV-2 UM Amp Buffer by inverting them 2-3 times (do not vortex), followed by a quick spin. All the other individual reagents can be homogenized by pulse vortexing for 3-5 seconds or by inverting 2-3 times, followed by a quick spin.

- The SARS-CoV-2 UM Prep Buffer inhibits RNases present in the clinical samples for the detection step, but it is not a virus-inactivating solution. All samples should be treated as potentially hazardous.
- Verify that the cycling conditions of the real-time RT-PCR platform are as specified in this protocol.
- Reagents may be aliquoted to avoid multiple freeze–thaw cycles.
- Freshly prepare the reaction mix (<2 h to the real-time RT-PCR plate launch).
- To minimize contamination, the sample and the real-time RT-PCR preparations should be done in distinct zones.

### Procedure:

**Sample preparation:** For respiratory tract specimens (nasal, oropharyngeal, and nasopharyngeal swabs), follow Step 1. For saliva specimens proceed to Step 2.

1. Respiratory tract specimens (nasal, oropharyngeal, and nasopharyngeal swabs):
  - 1a. Vortex the swab containing the sample vigorously.
  - 1b. Aliquot 50-200  $\mu$ l of the sample into 1.5mL PCR-free tubes
  - 1c. Perform heating step at 70°C for 10 min on a block heater.
  - 1d. Cool down the samples on ice for at least 5 min, then, keep the samples on ice or at 4°C.
2. Saliva samples:
  - 2a. Liquefaction (to facilitate pipetting): heat saliva sample at 95°C for 15 min (unspecified volume, container, or heating device).
  - 2b. Homogenize sample by gently pipetting up and down 8–10 times.
  - 2c. Aliquot 50  $\mu$ l of the sample into 1.5 ml PCR-free tube.
  - 2d. Perform heating step at 95°C for 15 min on a block heater, then, keep the sample at RT at least 5 min until their loading into PCR well or tube.
3. At first use, complete the SARS-CoV-2 UM Amp Buffer with the ROX reference dye.
  - 3a. Add 32.8  $\mu$ l of the ROX dye to 1 tube of SARS-CoV-2 UM Amp Buffer.
  - 3b. Close the lid containing the SARS-CoV-2 UM Amp Buffer and the ROX dye and invert the tube 3 times.
  - 3c. Spin down the SARS-CoV-2 UM Amp Buffer containing ROX dye at the bottom of the tube.

4. For a full cobas z 480 plate (96 wells), prepare an aliquot mix of the SARS-CoV-2 Amp Primers with the SARS-CoV-2 Internal Control.
  - 4a. Transfer the required volume of the SARS-CoV-2 Amp Primers and the SARS-CoV-2 Internal Control according to Table 11 into a new 1.5 mL PCR-free tube.
  - 4b. Close the lid and invert the tube 3 times or pulse vortex the tube for 3-5 s.
  - 4c. Spin down the SARS-CoV-2 Amp Primers containing the IC to bring the solution to the bottom of the tube.

**Table 11. SARS-CoV-2 Amp Primers + IC mix setup**

Reagents	SARS-CoV-2 Amp Primers + IC mix		Number of reactions Volume (µl)	
	Stock concentration	Final concentration	1 rxn	96 rxns (+ 20% extra volume*)
SARS-CoV-2 Amp Primers	3.45x	1x	7.25	835.2
SARS-CoV-2 Internal Control	166.67 cp/µl	10 cp/µl	1.5	172.8
Total SARS-CoV-2 Amp Primers + IC mix			8.75	1008

\* **Note:** Adjust the volumes of SARS-CoV-2 Amp Primers and SARS-CoV-2 Internal Control according to the number of samples to test. Consider extra volume to compensate for the dead volume.

5. Prepare a reaction mix according to Table 12 and mix thoroughly by inverting the tube 3 times.

**Table 12. Reaction mix setup**

Reagents	RT-PCR reaction mix		Number of reactions Volume (µl)	
	Stock concentration	Final concentration	1 rxn	96 rxns (+20% extra volume*)
SARS-CoV-2 UM Amp Buffer + ROX mix	4x	1x	6.25	720
SARS-CoV-2 Amp Primers + IC mix	2.9x	1x	8.75	1008
Total reaction volume		–	15.00	1728

\* **Note:** Adjust the volumes of SARS-CoV-2 UM Amp Buffer and SARS-CoV-2 Amp Primers according to the number of samples to test. Consider extra volume to compensate for the dead volume.

6. Dispense 8 µl of nuclease-free water to the well assigned to the NEC.
7. Load 10 µl of nuclease-free water into the well assigned to the NTC.

8. Dispense 2 µl of SARS-CoV-2 UM Prep Buffer into each well assigned to the NEC and the prepared samples.
9. Add 8 µl of the prepared sample to a well containing the SARS-CoV-2 UM Prep Buffer. Mix by pipetting up and down 5 times.
10. Add 15 µl of the reaction mix prepared in Step 5 to the wells dedicated to samples and controls (Figure 5 provided as an example). Mix by pipetting up and down 5 times.
11. Load 10 µl of the SARS-CoV-2 Positive Control into the appropriate well. Mix by pipetting up and down 5 times.
12. Seal the PCR plate well to prevent cross-contamination. Make sure to apply pressure uniformly across the entire plate to obtain a tight seal across individual wells.
13. Centrifuge the PCR plate briefly to collect liquid at the bottom of the well.
14. **First use:** In the Light Cycler 480 SW UDF 2.0.0 software, click on **open tools** and select **detection formats** to set the following excitation-emission combinations: 465-510 (FAM), 540-580 (HEX), and 610-670 (ATTO647N).
15. Set the real-time RT-PCR program according to Table 13 for 25 µl of reaction volume.  
**Note:** On top of the page, select **detection format** to choose the detection format created in Step 14.  
**Note:** Use a custom ramp rate of 1.6°C/sec in each of the 5 steps of the real-time RT-PCR program.  
**Note:** Data acquisition should be performed during the annealing/extension step.  
**Note:** Please refer to the *cobas z 480 Instruction for Use* for more details.
16. Place the plate in the real-time cycler (an example of a PCR plate layout is represented in Figure 5).
17. Start the run.
18. At the end of the run, analyze the results (see the Results section).

**Table 13. SARS-CoV-2 Prep&Amp UM program for the cobas z 480**

Steps	Time	Temperature (°C)	Ramp Rate (°C/sec)	Number of cycles	Analysis Mode
Reverse transcription	10 min	50	1.6	1	None
PCR initial heat activation	2 min	95	1.6	1	None
2-step cycling				40	Quantification
Denaturation	5 s	95	1.6		None
Annealing/Extension	30 s	58	1.6		Single
Cool down	1 min	37	1.6	1	None

	1	2	3	4	5	6	7	8	9	10	11	12
A	PC											
B	NTC											
C	NEC											
D	Sample 1											
E	Sample 2											
F	Sample 3											
G	...											
H												

**Figure 5. Example of plate layout on cobas z 480**

# Protocol: Sample Preparation and SARS-CoV-2 Detection on QuantStudio 5 Dx

This protocol is for preparing and detecting SARS-CoV-2 targets in human nasal, nasopharyngeal, or oropharyngeal swabs stored in transport media and in neat saliva samples on QuantStudio 5 Dx real-time RT-PCR instrument.

## Important points before starting.

- Verify that the expiration dates and storage conditions printed on the box and all component labels are followed. Do not use expired or incorrectly stored components.
- Use well-maintained and calibrated equipment.
- Pay attention to avoid contamination with RNases during the experiment and use nuclease-free plasticware.
- When using QuantStudio 5 Dx, ROX Dye must be added to the master mix tube before first use.

## Things to do before starting

- Respiratory samples may be kept at room temperature during preparation steps and reaction setup, but it is recommended to keep them on ice or at 4°C on a cooling rack.
- Saliva sample may be kept on ice or at 4°C on a cooling rack but it is recommended to keep them at room temperature (15–25°C) during preparation steps and reaction setup.
- The ROX dye is required when using the QuantStudio 5 .
- Before use, let the SARS-CoV-2 UM Prep Buffer, SARS-CoV-2 UM Amp Buffer, SARS-CoV-2 Amp Primers, SARS-CoV-2 IC, Water for NTC, and SARS-CoV-2 Positive Control completely thaw at (15–25°C). Keep tubes at room temperature and protected from light until use.
- Before use, homogenize the SARS-CoV-2 UM Prep Buffer and the SARS-CoV-2 UM Amp Buffer by inverting them 2-3 times (do not vortex), followed by a quick spin. All the other individual reagents can be homogenized by pulse vortexing for 3-5 seconds or by inverting 2-3 times, followed by a quick spin.

- The SARS-CoV-2 UM Prep Buffer inhibits RNases present in the clinical samples for the detection step but is not a virus-inactivating solution. All samples should be treated as potentially hazardous.
- Verify that the cycling conditions of the real-time RT-PCR platform are as specified in this protocol.
- Reagents may be aliquoted to avoid multiple freeze–thaw cycles.
- Freshly prepare the reaction mix (<2 h to the real-time RT-PCR plate launch).
- To minimize contamination, the sample and the real-time RT-PCR preparations should be done in distinct zones.

## Procedure

**Sample preparation:** For respiratory tract specimens (nasal, oropharyngeal, and nasopharyngeal swabs), follow Step 1. For saliva specimens proceed to Step 2.

1. Respiratory tract specimens (nasal, oropharyngeal, and nasopharyngeal swabs):
  - 1a. Vortex the swab containing the sample vigorously.
  - 1b. Aliquot 50-200  $\mu$ l of the sample into 1.5mL PCR-free tubes
  - 1c. Perform heating step at 70°C for 10 min on a block heater.
  - 1d. Cool down the samples on ice for at least 5 min, then, keep the samples on ice or at 4°C.
2. Saliva samples:
  - 2a. Liquefaction (to facilitate pipetting): heat saliva sample at 95 °C for 15 min (unspecified volume, container, or heating device).
  - 2b. Homogenize sample by gently pipetting up and down 8–10 times.
  - 2c. Aliquot 50  $\mu$ l of the sample into 1.5 ml PCR–free tube.
  - 2d. Perform heating step at 95°C for 15 min on a block heater, then, keep the sample at RT at least 5 min until their loading into PCR well or tube.
3. At first use, complete the SARS-CoV-2 UM Amp Buffer with the ROX Reference Dye.
  - 3a. Add 32.8  $\mu$ l of the ROX dye to a tube of SARS-CoV-2 UM Amp Buffer.
  - 3b. Close the lid containing the SARS-CoV-2 UM Amp Buffer and the ROX Dye and invert the tube 3 times.

- 3c. Spin down the SARS-CoV-2 UM Amp Buffer containing ROX Dye at the bottom of the tube.
4. For a full QuantStudio 5 Dx plate (96 wells), prepare an aliquot mix of the SARS-CoV-2 Amp Primers with the SARS-CoV-2 Internal Control.
  - 4a. Transfer the required volume of the SARS-CoV-2 Amp Primers and the SARS-CoV-2 Internal Control according to Table 14 into a new 1.5 mL PCR-free tube.
  - 4b. Close the lid and invert the tube 3 times or pulse vortex the tube for 3-5 s.
  - 4c. Spin down the SARS-CoV-2 Amp Primers containing the IC to bring the solution to the bottom of the tube.

**Table 14. SARS-CoV-2 Amp Primers + IC mix setup**

SARS-CoV-2 Amp Primers + IC mix			Number of reactions Volume (µl)	
Reagents	Stock concentration	Final concentration	1 rxn	96 rxns (+ 20% extra volume*)
SARS-CoV-2 Amp Primers	3.45x	1x	7.25	835.2
SARS-CoV-2 Internal Control	166.67 cp/µl	10 cp/µl	1.5	172.8
Total SARS-CoV-2 Amp Primers + IC mix			8.75	1008

\* **Note:** Adjust the volumes of SARS-CoV-2 Amp Primers and SARS-CoV-2 Internal Control according to the number of samples to test. Consider extra volume to compensate for the dead volume.

5. Prepare a reaction mix according to Table 15 and mix thoroughly by inverting the tube 3 times.

**Table 15. Reaction mix setup**

RT-PCR reaction mix			Number of reactions Volume (µl)	
Reagents	Stock concentration	Final concentration	1 rxn	96 rxns (+20% extra volume*)
SARS-CoV-2 UM Amp Buffer + ROX mix	4x	1x	6.25	720
SARS-CoV-2 Amp Primers + IC mix	2.9x	1x	8.75	1008
Total reaction volume		–	15.00	1728

\* **Note:** Adjust the volumes of SARS-CoV-2 UM Amp Buffer and SARS-CoV-2 Amp Primers according to the number of samples to test. Consider extra volume to compensate for the dead volume.

6. Dispense 8 µl of nuclease-free water to the well assigned to the NEC.
7. Load 10 µl of nuclease-free water into the well assigned to the NTC.
8. Dispense 2 µl of SARS-CoV-2 UM Prep Buffer into each well assigned to the NEC and the prepared samples.
9. Add 8 µl of the prepared sample to a well containing the SARS-CoV-2 UM Prep Buffer. Mix by pipetting up and down 5 times.
10. Add 15 µl of the reaction mix prepared in Step 5 to the wells dedicated to samples and controls (Figure 6 provided as an example). Mix by pipetting up and down 5 times.
11. Load 10 µl of the SARS-CoV-2 Positive Control into the appropriate well. Mix by pipetting up and down 5 times.
12. Seal the PCR plate well to prevent cross-contamination. Make sure to apply pressure uniformly across the entire plate to obtain a tight seal across individual wells.
13. Centrifuge the PCR plate briefly to collect liquid at the bottom of the well.
14. **First use:** The template must be generated in the QuantStudio 5 Dx TD software version 1.0.1 or higher and published before starting the run in the QuantStudio 5 Dx IVD software. Set up the template accordingly:

Note: In the Properties tab, configure Experiment type to Standard Curve and Run mode to Standard.

**Note:** In the **Method** tab, set up the real-time RT-PCR program for 25 µl reaction volume (Table 16).

**Note:** Data acquisition should be performed during the annealing/extension step.

**Note:** In the **Plate** tab, select **ROX** as **Passive Reference** and set up the FAM, VIC, and Cy5 as Targets with no Quencher (select **None**).

**Note:** Please refer to the *QuantStudio 5 Dx Instruction for Use* for more details.
15. In the QuantStudio 5 Dx IVD Software, load the template created previously in Step 14. Select the used wells and apply the FAM, VIC, and Cy5 Targets.
16. Place the plate in the real-time cycler (an example of a PCR plate layout is represented in the Figure 6).

17. Start the run.

18. At the end of the run, analyze the results (see the Results section).

**Table 16. SARS-CoV-2 Prep&Amp UM program for the QuantStudio 5 Dx**

Stage	Step	Time	Temperature (°C)	Number of cycles	Acquisition
Hold	1. Reverse transcription	10 min	50	1	No
	2. PCR initial heat activation	2 min	95	1	No
PCR	2-step cycling			40	
	Denaturation	5 s	95	1	No
	Annealing/Extension	30 s	58	1	FAM, VIC, and Cy5

	1	2	3	4	5	6	7	8	9	10	11	12
A	PC											
B	NTC											
C	NEC											
D	Sample 1											
E	Sample 2											
F	Sample 3											
G	...											
H												

**Figure 6. Example of plate layout on QuantStudio 5 Dx**

# Results

## Analysis on RGQ MDx 5plex HRM

On the RGQ MDx 5plex HRM, the data are analyzed with the Rotor-Gene Q software version 2.3.1 (or higher) according to the manufacturer’s instructions (Rotor-Gene Q MDx User Manual, Revision 7, September 2018).

For data analysis, the crop cycle must be used (Figure 7): Open the Raw Channel **Cycling A.Green**. Go to **Options > Crop Start Cycles** and Enter **5** in the dialog box. A new channel will be generated named **Cycling A(from 5).Green**. The same must be done for raw channels Red and Yellow to generate channels **Cycling A(from 5).Red** and **Cycling A(from 5).Yellow**.




Figure 7. Screenshot of setting crop cycles for the RGQ MDx 5plex HRM runs analysis

Open the analysis menu (Figure 8), and for each generated channel Cycling A(from 5), **apply** the following analysis parameters to maintain consistency between different analyses (Table 17).

**Table 17. Analysis parameters for the RGQ MDx 5plex HRM**

Channels	Green	Red	Yellow
Fluorescence threshold	0.03	0.03	0.03
Slope correction	Yes	Yes	Yes
Dynamic tube	Yes	Yes	Yes
Take-off point	No	10-20	10-20
Outlier Removal: Reaction Efficiency Threshold	Yes Enabled 0%	No	Yes Enabled -85%
Cropped start cycles	5	5	5
Cut-off cycles	Ct >38.00 is considered as 40.00	No	Ct >35.00 is considered as 40.00

In the RGQ software, run results are available in the quantitation results grid opened during the analysis. Data can be exported in comma separated value text (.csv) format: In the RGQ Software window, select **File > save as > Excel analysis sheet** . Make sure that all samples are selected before exporting the results (Figure 8).



**Figure 8. Screenshot of selected channels for applying the analysis parameters and exporting results (the RGQ MDx 5plex HRM runs analysis).**

## Analysis on ABI 7500 Fast Dx

On the ABI 7500 Fast Dx, the data are analyzed with the 7500 Fast System Software version 1.4.1 (or higher) according to the manufacturer's instructions. In the **setup** tab, select group of wells or the entire plate available in the analysis and right click to open the well inspector windows. The 3 fluorophores (FAM, VIC, and Cy5) must be selected, and **ROX** must be selected as **Passive reference**. The following parameters are needed for consistency between different analyses (Table 18).

**Table 18. Analysis parameters for the ABI 7500 Fast Dx**

Channels	FAM	Cy5	VIC
Passive dye	ROX	ROX	ROX
Fluorescence threshold	0.13	0.025	0.05
Baseline set	Auto	Auto	Auto
Cut-off cycles	Ct >39.00 is considered as 40.00	No	Ct > 35.00 is considered as 40.00

In the ABI SDS software, Ct values of a selected group of wells or the entire plate are available in the **data** sheet of the **Results** main section. Data can be exported in comma separated value text (.csv) format: In the SDS Software window, select **File > Export > Results** (menu item **Ct** can also be chosen). Select the format of the exported file as .csv.


## Analysis on CFX96 Dx

On the CFX96 Dx, the data are analyzed with CFX Manager Dx Software version 3.1.3090.1022 (or higher) according to the manufacturer's instructions. FAM, HEX, and Cy5 must be selected for all the wells used in the experiment. The following parameters are needed for consistency between different analyses (Table 19).

**Table 19. Analysis parameters for the CFX96 Dx**

Channels	FAM	HEX	Cy5
Cq determination mode: Single threshold	Yes	Yes	Yes
Baseline Setting:			
• subtracted curve fit	Yes	Yes	Yes
• Apply fluorescence drift correction	Yes	Yes	Yes
Threshold (RFU)	250	300	100
Cut-off cycles	Ct > 39.00 is considered as 40.00	Ct > 35.00 is considered as 40.00	No

In the CFX manager Dx Software, Ct values (called **Cq** on the software) of a selected group of wells or the entire plate are available in the data sheet of the **Quantification Data** section. Data can be exported as comma separated value text (.csv) by selecting **Export > Custom Export** and setting the parameters according to Figure 9.



**Figure 9. Raw data file parameters for the CFX96 Dx**

## Analysis on cobas z 480

On the cobas z 480, the data are analyzed with LightCycler 480 SW UDF version 2.0.0 (or higher) according to the manufacturer's instructions. Create a subset of samples, only with the wells used in the experiment. For each channel, create an **Abs Quant/Fit Points** Analysis page and use the following parameters for consistency between different experiments (Table 20).

**Table 20. Analysis parameters for the cobas z 480**

Channels	FAM (465-510)	HEX (540-580)	ATTO647N (610-670)
<b>Cycle range tab</b>			
• First - Last cycle	1-40	1-40	6-40
• Background	5/10	5/10	6/11
<b>Noise band tab</b>			
• Method	STD Multiplier	STD Multiplier	STD Multiplier
• STD Multiplier value	50	40	25
<b>Analysis tab</b>			
• Fit points	2	2	2
• Threshold method	Auto	Auto	Auto
<b>Cut off cycle</b>	Ct > 39.00 is considered as 40.00	Ct > 35.00 is considered as 40.00	No

In the LightCycler 480 SW UDF version 2.0.0 (or higher), Ct values (called **Cp** on the software) of a selected group of wells or the entire plate are available in the **analysis** section (Figure 10). Data can be exported as a text file (**.txt**) format per channel by right clicking on the results table and selecting **Export table**.




Figure 10. Screenshot of exported data in the LightCycler 480 SW UDF version 2.0.0 (or higher).

## Analysis on QuantStudio 5 Dx

On the QuantStudio 5 Dx, the data are analyzed with QuantStudio 5 Dx IVD Software version 1.0.1 (or higher) according to the manufacturer's instructions. In the **Assign Targets and Samples** window, the 3 fluorophores (FAM, VIC, and Cy5) must be selected for all the wells used in the experiment, and **ROX** must be selected as **Passive reference**. The following parameters are needed for consistency between different analysis (Table 21).

**Table 21. Analysis parameters for the QuantStudio 5 Dx**

<b>Channels</b>	<b>FAM</b>	<b>VIC</b>	<b>Cy5</b>
<b>Passive dye</b>	ROX	ROX	ROX
<b>Fluorescence threshold</b>	0.21	0.062	0.04
<b>Baseline set</b>	Auto	Auto	Auto
<b>Cut-off cycles</b>	Ct > 39.00 is considered as 40.00	Ct > 35.00 is considered as 40.00	No

Data can be exported in as a spreadsheet or text (**.xls**, **.xlsx**, **.txt**). In the **Export** tab of the QuantStudio 5 Dx IVD Software window, select all the option in the **content** section and select the option **unify the above content into one file**.

# Interpretation of Results

The positive control (PC), the N1, and the N2 genes are detected in the Green fluorescence channel with the RGQ MDx 5plex HRM or in the fluorescent channel FAM on the ABI 7500 Fast Dx, CFX96 Dx, cobas z 480, and QuantStudio 5 Dx.

The sampling control, composed of the RNase P, is detected in the Yellow fluorescence channel with the RGQ MDx 5plex HRM or in the fluorescence VIC/HEX with the ABI 7500 Fast Dx, CFX96 Dx, cobas z 480, and QuantStudio 5 Dx. Every clinical sample should display a sampling control amplification. In the PC, a Yellow amplification may be seen despite the absence of human sequences. In this case, a signal in the PC Yellow channel may be ignored because the strong fluorescence signal in the Green channel may bleed in the Yellow channel. The internal control (IC) is included in the SARS-CoV-2 Amp Primers. It is detected in the no template control (NTC), the no extraction control (NEC), the positive control (PC) and the clinical samples with the Red fluorescence channel with the RGQ MDx 5plex HRM or in the fluorescence channel Cy5/ATTO647N with the ABI 7500 Fast Dx, CFX96 Dx, cobas z 480, and QuantStudio 5 Dx. For a real-time RT-PCR run to be valid, a PC, NTC, and NEC controls must perform as shown in (Table 22, Table 23).

**Table 22. Run validity criteria and result interpretation for the RGQ MDx 5plex HRM**

Control	Detection in Green channel	Detection in Yellow channel	Detection in Red channel	Interpretation
Positive control (PC)	Ct ≤ 38.00	Indifferent	Indifferent	PC is valid.
	Ct > 38.00 or No Ct	Indifferent	Indifferent	PC is invalid.
No template control (NTC) or No extraction control (NEC)	Ct > 38.00 or No Ct	Ct > 35.00 or No Ct	Yes	NTC/NEC is valid.
	Any other combinations with amplification in Green or Yellow		Indifferent	NTC/NEC is invalid.

**Table 23. Run validity criteria and result interpretation for the ABI 7500 Fast Dx, CFX96 Dx, cobas z 480, and QuantStudio 5 Dx real-time RT-PCR instruments**

Control	Detection in FAM dye*	Detection in VIC/HEX dye*	Detection in Cy5/ATTO647N dye*	Interpretation
<b>Positive control (PC)</b>	Ct ≤ 39.00	Indifferent	Indifferent	PC is valid.
	Ct > 39.00 or No Ct	Indifferent	Indifferent	PC is invalid.
<b>No template control (NTC) or</b>	Ct > 39.00 or No Ct	Ct > 35.00 or No Ct	Yes	NTC/NEC is valid.
<b>No extraction control (NEC)</b>	Any other combinations with amplification in FAM or VIC/HEX		Indifferent	NTC/NEC is invalid.

To validate the tested samples, the samples must be amplified and detected as expected.

**Table 24. Sample validity criteria and results interpretation for the RQG MDx 5plex HRM**

Detection in Green channel	Detection in Yellow channel	Detection in Red channel	Interpretation
Ct ≤ 38.00	Indifferent	Indifferent	Sample is positive for SARS-CoV-2 RNA.
Ct > 38.00 or No Ct	Ct ≤ 35.00	Indifferent	Sample is negative, SARS-CoV-2 RNA is not detected.
Ct > 38.00 or No Ct	Ct > 35.00 or No Ct	Yes	Invalid sample. No or insufficient human material detected. Re-sampling is required.
Ct > 38.00 or No Ct	Ct > 35.00 or No Ct	No	Invalid sample. Real-time RT-PCR reaction is inhibited. A retest is required.

**Table 25. Sample validity criteria and results interpretation for the ABI 7500 Fast Dx, CFX96 Dx, cobas z 480, and QuantStudio 5 Dx real-time RT-PCR instruments.**

Detection in FAM dye*	Detection in VIC/HEX dye*	Detection in Cy5/ATTO647N dye*	Interpretation
Ct ≤ 39.00	Indifferent	Indifferent	Sample is positive.
Ct > 39.00 or No Ct	Ct ≤ 35.00	Indifferent	Sample is negative, SARS-CoV-2 is not detected.
Ct > 39.00 or No Ct	Ct > 35.00 or No Ct	Yes	Invalid sample. No human material detected. Re-sampling is required.
Ct > 39.00 or No Ct	Ct > 35.00 or No Ct	No	Invalid sample. Real time RT-PCR reaction is inhibited. A retest is required.

# Limitations

- For *in vitro* diagnostic use only.
- Results from the *artus* SARS-CoV-2 Prep&Amp UM Kit are not intended to be used as the sole basis for diagnosis, treatment, or other patient management decisions. Negative results do not preclude infection with SARS-CoV-2 and should not be the sole basis of a patient treatment decision.
- The product is to be used by personnel especially instructed and trained in *in vitro* diagnostics procedures.
- Strict compliance with the real-time RT-PCR platform's user manual (Rotor-Gene Q 5-plex HRM MDx, ABI 7500 Fast Dx, CFX96 Dx, cobas z 480, or QuantStudio 5 Dx) is required for optimal PCR results.
- Attention should be paid to expiration dates printed on the box and labels of all components. Do not use expired components.
- The performance of this test has not been established for saliva specimens from patients without signs and symptoms of respiratory infection.
- To avoid the risk of having a false-negative result in case low positive clinical sample is tested when blood traces are observed in the tube, this should be recorded, and if the sample returns a negative result when using the *artus* SARS-CoV-2 Prep&Amp UM Kit, the sample should be re-collected from the patient and should be tested again with the *artus* SARS-CoV-2 Prep&Amp UM Kit.

# Performance Characteristics

## Analytical sensitivity (Limit of detection)

The analytical sensitivity, or the limit of detection, is defined as the lowest concentration at which  $\geq 95\%$  of the tested samples generate a positive call. The LoD was assessed by analyzing serial dilutions of negative nasopharyngeal samples and liquified neat saliva samples prepared with high-titer stocks of inactivated viral particles obtained from commercial suppliers (ZeptoMetrix®). Two sample pools were used for each specimen for the LoD experiments. To confirm the established LoD concentration, the detection rate of all replicates must be  $\geq 95\%$  (at least 19/20 replicates must generate a positive signal).

The LoD concentration was verified on nasopharyngeal and neat saliva specimens on the claimed real-time RT-PCR platforms (RGQ MDx, ABI 7500 Fast Dx, CFX96 Dx, QuantStudio 5 Dx, and cobas z 480).

### Nasal, oropharyngeal and nasopharyngeal samples

The LoD is claimed at 950 cp/ml for the RGQ MDx, ABI 7500 Fast Dx, CFX96 Dx, and QuantStudio 5 Dx and 475 cp/ml for the cobas z 480 (see Table 26)

### Neat saliva samples

The LoD is claimed at 950 cp/ml for RGQ MDx and 1200 cp/ml for ABI 7500 Fast Dx, cobas z 480, QuantStudio 5 Dx, and CFX96 Dx (see Table 26).

**Table 26. LoD results summary for each real time RT-PCR platform**

Platform	Specimen type	LoD verified (cp/ml)
RGQ MDx	NPS	950
	Neat saliva	950
ABI 7500 Fast Dx	NPS	950
	Neat saliva	1200
QuantStudio5 Dx	NPS	950
	Neat saliva	1200
cobas z 480	NPS	475
	Neat saliva	1200
CFX96 Dx	NPS	950
	Neat saliva	1200

## Analytical specificity studies (Inclusivity and exclusivity/cross-reactivity)

### Inclusivity

The inclusivity of the *artus* SARS-CoV-2 Amp Primers and Probes has been assessed with an *in silico* analysis on sequences available in GISAID database ([www.gisaid.org](http://www.gisaid.org)). A total of 722,488 sequences (available at the 23/03/2021) were analyzed on COVID CG (<https://covidcg.org>), alimented by GISAID metadata. Sequences were aligned to the WIV04 reference sequence (100% identical to Wuhan-Hu-1/NC\_045512.2, except for the length of the poly-A tail) and the single nucleotide variations (SNVs) were analyzed in the genomic region targeted by the *artus* SARS-CoV-2 Prep&Amp UM Kit Primers and Probes. The prevalence of the identified SNVs stayed below 1%, as well as the frequency of the co-occurring mutations. There was no SNV located at the last 1 to 3 nucleotides from the 3' end in the respective oligonucleotides, which would be expected to impact performance. The *artus* SARS-CoV-2 Prep&Amp UM Kit is considered able to detect 100% of the published sequences.

## Exclusivity/Cross-reactivity

### [In silico analysis](#)

The exclusivity of the *artus* SARS-CoV-2 Amp Primers and Probes has been assessed with an *in silico* analysis on sequences stored in the NCBI databank. The *in silico* analysis showed that some of the tested pathogens have more than 80% homology with one of the *artus* SARS-CoV-2 primers or probes. Among these are *Candida albicans*, SARS-CoV-1, *Streptococcus pyogenes*, and *Streptococcus salivarius*. *Pseudomonas aeruginosa* had less than 80% homology with one of the primers/probes of the SARS-CoV-2 assay. However, the *artus* SARS-CoV-2 Amp Primers and Probes showed no possible amplification with the different sequences stored in the NCBI nr/nt database.

A total of 36 bacterial, viral, and fungal strains (Table 27. ) have been analyzed by *in silico* PCR with a limited potential amplicon size of 500 bp. Pathogen sequences were collected from the NCBI database, however, none of these pathogens showed amplification *in silico*. The table 27 shows the list of pathogen tested in silico.

**Table 27. List of *in silico* tested pathogens.**

Pathogens	Strain/Type	Taxonomy ID	<i>In silico</i> PCR results
Adenovirus Type 3	Type 3	45659	No match
Adenovirus Type 4	Type 4	28280	No match
Adenovirus Type 5	Type 5	28285	No match
Adenovirus Type 7A	Type 7A	85755	No match
Adenovirus Type 14	Type 14	10521	No match
Adenovirus Type 31	Type 31	10529	No match
<i>Bordetella pertussis</i>	A639	520	No match
<i>Candida albicans</i>	Z006 SC5314	5476	No possible amplification*†
<i>Chlamydia pneumoniae</i>	CWL-029 TW-183	115713	No match
Enterovirus	Type 68	42789	No match

\* Sequence match with one of the primers/probes showed <80% homology.

† Sequence match with one of the primers/probes showed ≥80% homology.

**(Continued on next page)**

**Table 27. (Continued from previous page)**

Pathogens	Strain/Type	Taxonomy ID	<i>In silico</i> PCR results
<i>Haemophilus influenzae</i>	KW20	727	No match
Human coronavirus	229E	11137	No match
Human coronavirus	NL63	277944	No match
Human coronavirus	HKU-1	290028	No match
Human coronavirus OC43	OC43	31631	No match
Human Coronavirus	MERS-CoV	1335626	No match
Human Metapneumovirus	n/a	162145	No match
Influenza A	H1N1	114727	No match
Influenza A	H3N2	119210	No match
Influenza B	n/a	11520	No match
<i>Mycoplasma pneumoniae</i>	M129 FH	272634	No match
Parainfluenza virus	Type 1	12730	No match
Parainfluenza virus	Type 2	2560525	No match
Parainfluenza virus	Type 3	11216	No match
Parainfluenza virus	Type 4	2560526	No match
<i>Pneumocystis jirovecii</i>	RU7	42068	No match
<i>Pseudomonas aeruginosa</i>	PAO1	287	No possible amplification*
Respiratory syncytial virus	Type A (RSV-A)	208893	No match
Respiratory syncytial virus	Type B (RSV-B)	208895	No match
Rhinovirus	Type A	147711	No match
Rhinovirus	Type B	147712	No match
SARS-coronavirus	Tor2	694009	No possible amplification†
<i>Staphylococcus epidermidis</i>	n/a	1282	No match
<i>Streptococcus pyogenes</i>	n/a	1314	No possible amplification†
<i>Streptococcus salivarius</i>	ATCC® BAA-1024D-5 CCHSS3	1304	No possible amplification†
<i>Streptococcus pneumoniae</i>	ATCC 700669 NCTC11032	1313	No match

\* Sequence match with one of the primers/probes showed <80% homology.

† Sequence match with one of the primers/probes showed ≥80% homology.

In vitro analysis

The cross-reactivity was verified *in vitro* with pathogens showing  $\geq 80\%$  homology with the SARS-CoV-2 Amp Primers in the *in silico* analysis. Samples were prepared by spiking potential cross-reactive organisms into nasopharyngeal swab matrix at  $10^6$  cp/ml, except for SARS-CoV-1 which was tested undiluted according to its supplier’s recommendation. None of these pathogens showed *in vitro* cross-reactivity.

The microbial interference of the *artus* SARS-CoV-2 Prep&Amp UM Kit assay has been assessed *in vitro* on a panel of recommended pathogens (Table 28). Samples were prepared by spiking a maximum of 5 pathogens - at 105 TCID50/mL for viral targets,  $10^6$  cp/mL for bacterial and fungal targets, or at the highest concentration possible based on the stock concentration - into negative nasopharyngeal swabs spiked at  $2.87 \times \text{LoD}$  with inactivated SARS-CoV-2 particles (Zeptomatrix). The NATrol™ Panels and the SARS-CoV-1 were spiked directly with inactivated SARS-CoV-2 viral particles (Zeptomatrix) at  $2.87 \times \text{LoD}$ . The results for each tested microorganism pools and the respective concentrations are summarized below.

Table 28 shows the list of tested pathogens in microbial interference.

**Table 28. List of *in vitro* tested pathogens in microbial interference.**

Pool ID/ Sample ID	Microorganism	Source	Final concentration	Unit	Result
Pool 1	SARS-CoV-2	Zeptomatrix (NATSARS(COV2)-ERC)	2.72E+03	cp/ml	No interference
	Human coronavirus 229E	Zeptomatrix (0810229CFHI)	1.43E+05	TCID50/ml	
	Human coronavirus OC43	Zeptomatrix (0810024CFHI)	5.86E+04	TCID50/ml	
	Human coronavirus NL63	Zeptomatrix (0810228CFHI)	2.84E+04	TCID50/ml	
	Adenovirus T3	Zeptomatrix (0810016CFHI)	1.43E+05	TCID50/ml	
	Parainfluenza virus 1	Zeptomatrix (0810014CFHI)	9.14E+06	TCID50/ml	
Pool 2	SARS-CoV-2	Zeptomatrix (NATSARS(COV2)-ERC)	2.72E+03	cp/ml	No interference
	Adenovirus T31	Zeptomatrix (0810073CFHI)	1.67E+04	TCID50/ml	
	Parainfluenza virus 2	Zeptomatrix (0810015CFHI)	4.29E+04	TCID50/ml	
	Influenza B Florida/02/2006	Zeptomatrix (0810037CFHI)	1.43E+05	TCID50/ml	
	Rhinovirus T 1A	Zeptomatrix (0810012CFNHI)	2.86E+04	TCID50/ml	

(Continued on next page)

Table 28 (Continued from previous page)

Pool ID/ Sample ID	Microorganism	Source	Final concentration	Unit	Result
Pool 3	SARS-CoV-2	Zeptomatrix (NATSARS(COV2)-ERC)	2.72E+03	cp/ml	No interference
	Parainfluenza Virus T3	Zeptomatrix (0810016CFHI)	1.43E+07	TCID50/ml	
	<i>Haemophilus influenzae</i>	ATCC (51907D-5)	1.00E+06	CFU/ml	
	<i>Streptococcus pneumoniae</i>	ATCC (700669DQ)	3.30E+06	CFU/ml	
	<i>Candida albicans</i>	Zeptomatrix (0801504DNA)	1.00E+06	CFU/ml	
	<i>Staphylococcus epidermidis</i>	ATCC (12228DQ)	4.60E+06	CFU/ml	
Pool 4	SARS-CoV-2	Zeptomatrix (NATSARS(COV2)-ERC)	2.73E+03	cp/ml	No interference
	Adenovirus T7A	Zeptomatrix (0810021CFHI)	1.02E+06	TCID50/ml	
	<i>Streptococcus pyogenes</i>	ATCC (700294DQ)	1.00E+07	CFU/ml	
	<i>Mycoplasma pneumoniae</i>	Zeptomatrix (0801579DNA)	1.00E+08	CFU/ml	
	<i>Pseudomonas aeruginosa</i>	ATCC (47085DQ)	1.00E+07	CFU/ml	
Pool 5	SARS-CoV-2	Zeptomatrix (NATSARS(COV2)-ERC)	2.72E+03	cp/ml	No interference
	Respiratory syncytial virus RSVA	Zeptomatrix (0810482CFHI)	7.14E+04	TCID50/ml	
	Influenza A H1N1 California	Zeptomatrix (0810165CFHI)	1.43E+04	TCID50/ml	
	Enterovirus Type 68 Major Group	Zeptomatrix (0810300CFHI)	1.43E+05	TCID50/ml	
	Adenovirus T14	Zeptomatrix (0810108CFHI)	2.86E+04	TCID50/ml	
Pool 6	SARS-CoV-2	Zeptomatrix (NATSARS(COV2)-ERC)	2.73E+03	cp/ml	No interference
	MERS-coronavirus	Zeptomatrix (0810575CFHI)	1.43E+04	TCID50/ml	
	AdenoVirus T4	Zeptomatrix (0810070CFHI)	1.43E+05	TCID50/ml	
	Human Metapneumovirus (hMPV) Type B	Zeptomatrix (0810156CFHI)	7.14E+03	TCID50/ml	
	Respiratory Syncytial Virus Type B (RSV-B)	Zeptomatrix (0810040CFHI)	1.43E+03	TCID50/ml	

(Continued on next page)

Table 28 (Continued from previous page)

Pool ID / Sample ID	Microorganism	Source	Final concentration	Unit	Result
Pool 7	SARS-CoV-2	Zeptomatrix (NATSARS(COV 2)-ERC)	2.73E+03	cp/ml	No interference
	Adenovirus T5	Zeptomatrix (0810020CFHI)	6.43E+05	TCID50/ml	
	Parainfluenza virus 4B	Zeptomatrix (0810060BCFH I)	7.14E+04	TCID50/ml	
	Influenza A H3N2 Switzerland/9715293/13	Zeptomatrix (0810511CFHI)	2.86E+04	TCID50/ml	
	<i>Streptococcus salivarius</i>	Zeptomatrix (BAA-1024D-5)	1.00E+06	CFU/ml	
Pool 8	SARS-CoV-2	Zeptomatrix (NATSARS(COV 2)-ERC)	2.73E+03	cp/ml	No interference
	NATrol Panel RP1 (Influenza A H3N2 (Brisbane/10/07), Influenza A H1N1 (NY/02/2009), Rhinovirus (Type 1A), Adenovirus T3, Parainfluenza T1, Parainfluenzavirus T4, Metapneumovirus (Peru 6-2003) <i>C. pneumoniae</i> (CWL-029), <i>M. pneumoniae</i> (M129), Coxsackievirus (Type A1))	Zeptomatrix (MDZ001)	Unknown*	N/A	
Pool 9	SARS-CoV-2	Zeptomatrix (NATSARS(COV 2)-ERC)	2.73E+03	cp/ml	No interference
	NATrol Panel RP2 (Influenza A H1 (New Caledonia/20/99), Influenza B (Florida/02/06), RSV-A, Parainfluenza T2, Parainfluenza T3, Coronavirus HKU recombinant, Coronaviruses (OC43, NL63, 229E), <i>Bordetella pertussis</i> (A639))	Zeptomatrix (MDZ001)	Unknown*	N/A	
Pool 10	SARS-CoV-2	Zeptomatrix (NATSARS(COV 2)-ERC)	2.73E+03	cp/ml	No interference
	SARS-CoV-1	Zeptomatrix (NATSARS-ST)	Unknown*	N/A	

\* Concentration not communicated by the supplier.

## Interfering substances

### Nasal, oropharyngeal, and nasopharyngeal swab samples

The effect of putative interfering substances (for the substances listed in Table 29) has been assessed on the *artus* SARS-CoV-2 Prep&Amp UM Kit performance. Tests were performed in 3 pools of negative nasopharyngeal swabs and in 3 pools of positive nasopharyngeal swabs spiked at 4 x LoD with inactivated SARS-CoV-2 viral particles (Zeptomatrix). The experiments were performed on the RGQ MDx 5plex HRM platform (across 4 instruments) by 1 operator with 1 pilot kit.

Each pool was split into 2 to test either the interfering substance dissolved in a solvent (test sample) or the solvent alone (control sample). Hit rates in the Green and in the Red fluorescence channels were compared between the test and its corresponding control samples. In absence of interference, the test and its corresponding control samples have the same hit rate.

Table 29 shows that none of the tested substances interfere with the *artus* SARS-CoV-2 Prep&Amp UM Kit performance in the Green fluorescence channel.

**Table 29. List of interfering substances and the hit rates obtained in Green channel.**

Interfering substances	Function	Tested concentration	Hit Rate results in negative nasopharyngeal swab	Hit rate results in positive (4x LoD) nasopharyngeal swab
<b>Tobramycin</b>	Systemic antibiotic	1 mg/ml	No interference 0/15	No interference 15/15
<b>Mupirocin</b>	Nasal antibiotic ointment	6.6 mg/ml	No interference 0/15	No interference 15/15
<b>Fluticasone</b>	Nasal corticosteroid	5% (v/v)	No interference 0/15	No interference 15/15
<b>Menthol (Throat lozenges)</b>	Oral anesthetic and analgesic	0.5 mg/ml	No interference 0/15	No interference 15/15
<b>Oxymetazoline</b>	Nasal spray	10% (v/v)	No interference 0/15	No interference 15/15

[Continued on next page](#)

Table 29 (continued from previous page)

Interfering substances	Function	Tested concentration	Hit Rate results in negative nasopharyngeal swab	Hit rate results in positive (4x LoD) nasopharyngeal swab
<b>Osetamivir</b>	Anti-viral drug	3.3 mg/ml	No interference 0/15	No interference 15/15
<b>Mucin (Bovine submaxillary gland type I-S)</b>		2.5 mg/ml	No interference 0/15	No interference 15/15
<b>Whole Blood</b>		4% (v/v)	No interference 1/15*	No interference 15/15

\* An amplification corresponding to an artefact has been detected.

## Neat saliva samples

The effect of eight putative interfering substances (for the substances listed in Table 30) has been assessed on the performance of the *artus* SARS-CoV-2 Prep&Amp UM Kit. Tests were performed in 1 pool of negative neat saliva samples, which has been split in half to perform two dilution levels: (1) negative neat saliva samples, and (2) contrived positive neat saliva samples (obtained by spiking at 3x LoD (3600 cp/ml) with inactivated SARS-CoV-2 viral particles (Zeptometrix) into the negative pool). Neat saliva samples were tested with the cobas z 480 platform by 3 operators with one commercial kit.

For each interfering substance, the sample replicates were split into 2 to test either the interfering substance dissolved in a solvent (test sample) or the solvent alone (control sample). Hit rates in the Green, Red, and Yellow fluorescence channels were compared between the test and its corresponding control samples. In absence of an interference, the test and its corresponding control samples have the same hit rate.

In terms of qualitative (sample status) analysis, the eight interfering substances tested (see Table 30) do not impact the results of the *artus* SARS-CoV-2 Prep&Amp UM Kit on positive and negative saliva samples .

Table 30 shows that none of the tested substances interfere with the *artus* SARS-CoV-2 Prep&Amp UM Kit performance in the Green fluorescence channel.

**Table 30. List of the interfering substance and the hit rates obtained in Green channel.**

Interfering substance*	Function	Tested Concentration	Hit Rate Results in negative neat saliva samples	Hit Rate Results in positive (3 to 5x LoD) neat saliva samples
<b>Whole blood</b>	Endogenous substance: Human gDNA, leukocytes, erythrocytes	1% v/v	No interference* 0/8	No interference* 8/8
<b>Altoids®</b>	Candy	2% w/v	No interference 0/8	No interference 8/8
<b>Aspirin</b>	Anti-inflammatory drug	1% w/v	No interference 0/8	No interference 8/8
<b>Listerine®</b>	Antiseptic mouthwash	1% v/v	No interference 0/8	No interference 8/8
<b>Ricola®</b>	Candy	1% w/v	No interference 0/8	No interference 8/8
<b>Colgate® Total SF Whitening™ Toothpaste</b>	Teeth whitening toothpaste	0.1% w/v	No interference 0/8	No interference 8/8
<b>Tussidane® Sirop</b>	Drug for dry cough	1% v/v	No interference 0/8	No interference 8/8
<b>Pulmofluide®</b>	Drug for wet cough	1% v/v	No interference 0/8	No interference 8/8

\* For the whole blood, an interfering effect was observed for the IC detection in the Red channel (10-40% of inhibition) without impacting the sample validity. On the Green channel, the sample status was not affected by the whole blood, but a slight Ct drift was observed (average 1.35 Ct later with whole blood compared to the control sample).

To avoid the risk of having a false negative in case of low positive clinical sample tested if blood traces are observed in the tube, this should be recorded, and if the sample returns a negative result when using the *artus* SARS-CoV-2 Prep&Amp UM Kit, neat saliva should be re-collected from the patient, and the sample should be tested again with the *artus* SARS-CoV-2 Prep&Amp UM Kit.

## Sample stability study

The samples stability study was performed to assess the impact of different sample storage conditions on the qualitative (hit rate analysis) and quantitative (Ct drift analysis) results of the *artus* SARS-CoV-2 Prep&Amp UM kits. Experiments were performed by analyzing two dilution levels: (1) negative samples and (2) contrived positive samples obtained by spiking of inactivated SARS-CoV-2 viral particles (Zeptomatrix). To confirm the stability of the samples (saliva and NPS), it was required that  $\geq 95\%$  of the replicates give the same hit rate and a Ct drift  $\leq 10\%$  than the time point 0 for each stability condition occurs.

### Nasal, oropharyngeal, and nasopharyngeal samples:

The different stability conditions tested are listed in the Table 31. Tests were performed using 3 sample pools. Negative NPS samples, 5x LoD (4750 cp/ml) of contrived positive NPS samples, and three lots of batch release samples BRS1 (N2 string, 1000 cp/10 $\mu$ L), BRS2 (RNAse P gblock, 1000 cp/10 $\mu$ L), and BRS3 (N1 string, 1000 cp/10 $\mu$ L) were tested with the ABI 7500 Fast Dx platform.

From the qualitative and the quantitative analysis results, the NPS samples storage conditions tested did not impact the hit rate (the same status detected as expected) and did not lead to significant Ct drifts of the results of the *artus* SARS-CoV-2 Prep&Amp UM kit. Thus, performance of the kit was stable despite all different storage conditions of NPS samples tested (see Table 31).

Table 31 shows the nasopharyngeal samples stability conditions

**Table 31. Nasopharyngeal sample stability conditions.**

Conditions	Sample stability claim
F/T	3 F/T
4°C (2°C to 8°C)	72 h
-70°C	2 weeks

## Neat saliva samples

The different stability conditions tested are listed in the Table 32. Tests were performed using 2 sample pools. Negative neat saliva samples and 3xLoD (3600 cp/ml) of contrived positive neat saliva samples were tested with ABI 7500 Fast Dx platform.

From the qualitative and the quantitative analysis results, the storage conditions tested did not impact the hit rate (the same status detected as expected) and did not lead to significant Ct drifts of the results of the *artus* SARS-CoV-2 Prep&Amp UM kit. Thus, performance of the kit was stable despite different storage conditions of neat saliva samples tested.

Table 32 shows the neat saliva stability conditions.

**Table 32. Neat Saliva sample stability condition**

Conditions	Sample stability claim
F/T	3 F/T
RT (18°C to 26°C)	72 h
4°C (2°C to 8°C)	72 h
Combined condition: (6 h at RT combined with 72 h at 4°C (2 to 8°C) combined with 8 days at -20°C (-30°C to -15°C)	6h RT then 72 h at 4°C (2 to 8°C) then 7 days -20°C (-30°C to -15°C)
-20°C (-30°C to -15°C)	1 month (30.5 days)

## Precision

The Precision study assessed the reproducibility (the same sample is repeated in different runs and conditions: 5 days, 3 kit lots, 3 operators, and 2 instruments) and the repeatability (the same sample is repeated in the same run and condition). Tests were performed on negative nasopharyngeal samples and negative nasopharyngeal samples spiked at 5 x LoD on the RGQ MDx.

For each dilution level, 204 data points were collected. Repeatability and reproducibility data were used to determine the standard deviation (SD) and the coefficient of variation (%CV) for

the SARS-CoV-2 targets in the Green, Yellow, and Red channels. Table 33 shows that the *artus* SARS-CoV-2 Prep&Amp UM Kit has an overall precision of 0.63 SD (2.03% CV) in the Green channel, 0.54 SD (2.22 %CV) in the Yellow channel, and of 1.28 SD (4.10 %CV) in the Red channel.

**Table 33. Standard deviation and coefficient of variation of the *artus* SARS-CoV-2 Prep&Amp UM Kit.**

Samples and detection channel	Total	Day-to-day	Batch-to-batch	Operator-to-operator	Instrument-to-instrument	Run-to-run	Within run
	Standard deviation (SD) (Coefficient of variation (%CV))						
Negative NPS Yellow channel	0.54 (2.22)	0.09 (0.37)	0.10 (0.42)	0.06 (0.27)	0.11 (0.47)	0.09 (0.36)	0.50 (2.05)
Negative NPS Red channel	1.15 (3.68)	0.0 (0.00)	0.55 (1.76)	0.00 (0.00)	0.12 (0.40)	0.39 (1.26)	0.92 (2.96)
Spiked NPS Green channel	0.63 (2.03)	0.18 (0.59)	0.31 (1.00)	0.00 (0.00)	0.08 (0.25)	0.00 (0.00)	0.51 (1.64)
Spiked NPS Yellow channel	0.47 (1.93)	0.13 (0.53)	0.24 (0.98)	0.05 (0.20)	0.18 (0.73)	0.00 (0.00)	0.33 (1.38)
Spiked NPS Red channel	1.28 (4.10)	0.12 (0.37)	0.58 (1.84)	0.11 (0.34)	0.00 (0.00)	0.49 (1.57)	1.02 (3.27)

## Clinical performance

### Nasopharyngeal swabs

The clinical performance of the *artus* SARS-CoV-2 UM Prep&Amp assay was evaluated using retrospective nasopharyngeal swab specimens in transport medium, consisting of 150 clinical specimens.

All specimens were collected from patients with signs and symptoms of COVID-19 infection and were stored frozen until use.

The clinical validation was performed on the ABI 7500 Fast Dx. Table 34 reports the performance of the *artus* SARS-CoV-2 Prep&Amp UM Kit against a reference method.

**Table 34. Clinical performance of the *artus* SARS-CoV-2 Prep&Amp UM Kit against a reference method.**

Sample Status	N	% of Positive	95% CI	% Negative	95% CI
Positive	52	98.1 (51/52)	89.9 – 99.7	1.9 (1/52)	-
Negative	98	5.1 (5/98)	-	94.9 (93/98)	88.7 – 97.8

Discordant results were evaluated by a third method and re-analyzed with a contingency table. The overall clinical performance results are expressed as Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) and are shown in Table 35.

**Table 35. Clinical performance of the *artus* SARS-CoV-2 Prep&Amp UM Kit after discordant results analysis.**

Sample Status	N	% Positive	95% CI	% Negative	95% CI
Positive	52	98.1 (51/52)	89.9 – 99.7	1.9 (1/52)	-
Negative	98	5.1 (5/98)	-	94.9 (93/98)	88.7 – 97.8

Listed below are the fraction of samples in agreement and positive and negative percent agreement (PPA and NPA, respectively) with the expected samples statuses:

Positive Percent Agreement (PPA):  $51/52 = \mathbf{98.1\%}$  (95% CI: 89.9% - 99.7%)

Negative Percent Agreement (NPA):  $93/98 = \mathbf{94.9\%}$  (95% CI: 88.6% - 97.8%)

## Nasopharyngeal swabs including asymptomatic individuals

The clinical performance of the *artus* SARS-CoV-2 UM Prep&Amp assay was evaluated using retrospective nasopharyngeal swab specimens in transport medium, consisting of 153 clinical specimens. All specimens were collected from patients without symptoms or other reasons to suspect COVID-19 infection.

The clinical validation was performed on the ABI 7500 Fast Dx. Sixteen samples were excluded from analysis after testing with the *artus* SARS-CoV-2 Prep&Amp UM Kit due to an invalid status according to the sample validity criteria (Table 23).

Table 36 reports the performance of the *artus* SARS-CoV-2 Prep&Amp UM Kit against a reference method, which is expressed as positive percent agreement (PPA) and negative percent agreement (NPA).

**Table 36. Clinical performance of the *artus* SARS-CoV-2 Prep&Amp UM Kit against a reference method**

Sample Status	N	% of Positive	95% CI	% Negative	95% CI
Positive	50	64.0 (32/50)	50.1 – 75.9	36.0 (18/50)	–
Negative	87	1.15 (1/87)	–	98.85 (86/87)	93.8 – 99.8

Nineteen discordant results were evaluated by a third method and re-analyzed with a contingency table. The overall clinical performance results are expressed as positive percent agreement (PPA) and negative percent agreement (NPA) and are shown in Table 37.

**Table 37. Clinical performance of the *artus* SARS-CoV-2 Prep&Amp UM Kit after discordant results analysis**

Sample Status	N	% of Positive	95% CI	% Negative	95% CI
Positive	32	100.0 (32/32)	89.3 – 100.0	0 (0/32)	–
Negative	105	0.95 (1/105)	–	99.05 (104/105)	94.8 – 99.8

Eighteen false negative samples were reclassified as true negatives, while the one false positive remained false positive.

Listed below are the fraction of samples in agreement and positive and negative percent agreement (PPA and NPA, respectively) with the expected samples statuses:

Positive Percent Agreement (PPA):  $32/32 = 100.0\%$  (95% CI: 89.3% - 100.0%)

Negative Percent Agreement (NPA):  $104/105 = 99.05\%$  (95% CI: 94.8% - 99.8%)

### Neat saliva samples

The clinical performance of the *artus* SARS-CoV-2 UM Prep&Amp assay was evaluated using neat saliva specimens, consisting of 142 saliva specimens.

All specimens were collected from patients with signs and symptoms of COVID-19 infection. The clinical validation was performed on the ABI 7500 Fast Dx. Twelve samples were excluded from analysis after testing with the *artus* SARS-CoV-2 Prep&Amp UM Kit and also the reference method due to both tests yielding an invalid status according to the sample validity criteria.

Table 38 reports the performance of the *artus* SARS-CoV-2 Prep&Amp UM Kit against a reference method.

**Table 38. Clinical performance of the *artus* SARS-CoV-2 Prep&Amp UM Kit against a reference method.**

Sample Status	N	% of Positive	95% CI	% Negative	95% CI
Positive	45	93.33 (42/45)	82.14 – 97.71	6.67 (3/45)	-
Negative	85	0 (0/85)	-	100 (85/85)	95.68 – 100.00

Three discordant results were evaluated by a third method and re-analyzed with a contingency table. The overall clinical performance results are expressed as positive percent agreement (PPA) and negative percent agreement (NPA) and are shown in Table 39.

**Table 39. Clinical performance of the *artus* SARS-CoV-2 Prep&Amp UM Kit after discordant results analysis.**

Sample Status	N	% Positive	95% CI	% Negative	95% CI
Positive	43	97.67 (42/43)	87.94 – 99.59	2.32 (1/43)	-
Negative	87	0 (0/87)	-	100 (87/87)	95.77 – 100.00

Two false-negative results were reclassified as true negatives, while one false-negative result remained false negative.

Listed below are the fraction of samples in agreement and positive and negative percent agreement (PPA and NPA, respectively) with the expected samples statuses:

Positive Percent Agreement (PPA):  $42/43 = 97.67\%$  (95% CI: 87.94% - 99.59%)

Negative Percent Agreement (NPA):  $87/87 = 100.00\%$  (95% CI: 95.77% - 100.00%)

# References

1. CUI J *et al.* (2019) Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol* **17**, 181-192
2. Gagneur *et al.* (2002) Infections nosocomiales à coronavirus humains chez le nouveau-né. *Arch Pédiatr* **9**, 61-69
3. HU *et al.* (2020) Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol* **6**:1-14.
4. Mackay IM. (2004) Real-time PCR in the microbiology laboratory. *Clin Microbiol. Infect* **10**(3), 190–212
5. European Commission. (2020) Current performance of COVID-19 test methods and devices and proposed performance criteria. 16 April 2020. <https://ec.europa.eu/docsroom/documents/40805/attachments/1/translations/en/renditions/native>

# Troubleshooting Guide

This troubleshooting guide may help solve any problems that may arise. For more information, see also the Frequently Asked Questions page at our Technical Support Center: [www.qiagen.com/FAQ/FAQList.aspx](http://www.qiagen.com/FAQ/FAQList.aspx).

## Comments and suggestions

---

### Weak or No Green signal (FAM) in Positive Control (PC)

- |   |  |
|---|--|
| a) The selected fluorescence channel for RT-PCR data analysis does not comply with the protocol.  | For data analysis, select the fluorescence channel FAM (Green) for the analytical SARS-CoV-2 RT-PCR targets, the fluorescence channel HEX/VIC/JOE (Yellow) for the sampling control and the Cy5/Atto (Red) for the internal control.   |
| b) Incorrect programming of the temperature profile.  | Compare the RT-PCR program with the protocol.  |
| c) Incorrect configuration of the PCR reaction  | Verify your work steps through the pipetting scheme and repeat the PCR, if necessary.  |
| d) The storage conditions for one or more kit components did not comply with the instructions, or the <i>artus</i> SARS-CoV-2 RT-PCR kit has expired. | Follow the storage conditions and verify the reagents' expiration date and use a new kit, if necessary.  |
| e) Incorrect configuration of the real time RT-PCR platform during the data configuration.  | Apply the recommended configurations related to your real time RT-PCR platform that are described in this manual.  |
| f) The PCR was inhibited.   | Follow the good practices in molecular biology laboratory to avoid the introduction of contaminants.<br>Make sure that workspace and instruments are decontaminated at regular intervals.<br>Follow the protocol mentioned in this manual. Check the expiration date of the reagent and use a new kit, if necessary. Repeat the assay with another sample. |

### Green signal (FAM) in the No Template Control or in the No Extraction Control

- |   |   |
|---|---|
| Contamination with SARS-CoV-2 sequences occurred during the RT-PCR plate preparation. | Repeat the RT-PCR with new reagents.<br>Follow the good practices in molecular biology laboratory to avoid the introduction of contaminants. Follow the protocol mentioned in this handbook.<br>Make sure that workspace and instruments are decontaminated at regular intervals. |
|---|---|

## Comments and suggestions

---

### Weak or no Red signal (Cy5/Atto) from the internal control

- |  |  |
|--|--|
| a) An interferent has been introduced in the RT-PCR reaction. The PCR is inhibited.        | Follow the good practices in molecular biology laboratory to avoid the introduction of contaminants.<br>Make sure that workspace and instruments are decontaminated at regular intervals.<br>Follow the protocol mentioned in this manual.<br>Repeat the experiment with a newly collected sample.   |
| b) The internal control is degraded.   | Follow the good practices in molecular biology laboratory to avoid the introduction of RNases. Follow the recommendations mentioned in this manual.<br>Make sure that workspace and instruments are decontaminated at regular intervals.<br>Follow the storage conditions and check the reagents' expiration date and use a new kit, if necessary. |
| c) Incorrect configuration of the real time RT-PCR platform during the data configuration. | Apply the recommended configurations related to your real time RT-PCR platform that are described in this manual.  |

### Weak or no Yellow signal (VIC/HEX) of the sampling control

- |  |  |
|--|--|
| a) The clinical sample is degraded.  | Follow the recommendations provided by the collection device supplier for their storage, handling and transport.<br>Follow the protocol mentioned in this manual, including the sample preparation steps with the SARS-CoV-2 UM Prep buffer.<br>Follow the storage conditions and check the reagents' expiration date, such as the SARS-CoV-2 UM Prep buffer, and use a new kit, if necessary. |
| b) The specimen was not properly collected. Not enough human cells were collected on the swab or transferred in the transport media. | Follow the recommendations provided by the collection device supplier for the specimen collection and the specimen handling.   |
| c) Incorrect configuration of the real-time RT-PCR platform during the data configuration.   | Apply the configurations related to your real time RT-PCR platform that are described in this manual.  |

# Symbols

The following symbols may appear in the instructions for use or on the packaging and labelling:

Symbol	Symbol definition
	Contains reagents sufficient for 768 or 3072 reactions
	Use by
	In vitro diagnostic medical device
	Catalogue number
	Lot number
	Components
	Contains
	Number
	Global Trade Item Number
R <sub>n</sub>	R is for revision of the Instructions for Use and n is the revision number
	Temperature limitation

**Symbol**

**Symbol definition**

---



Manufacturer



Consult instructions for use



Keep away from sunlight



Warning/caution

## Contact Information

For technical assistance and more information, please contact the QIAGEN Technical Services at [support.qiagen.com](https://support.qiagen.com).

# Ordering Information

Product	Contents	Cat. no.
<i>artus</i> SARS-CoV-2 Prep&Amp UM Kit (768)	For 768 reactions: Preparation Buffer, ROX dye, Master Mix, Primers and Probes, Internal Control, Water (NTC), and Positive Control	4511460
<i>artus</i> SARS-CoV-2 Prep&Amp UM Kit (3072)	For 3072 reactions: Preparation Buffer, ROX dye, Master Mix, Primers and Probes, Internal Control, Water (NTC), and Positive Control	4511469
<b>Instrument and accessories</b>		
PCR tubes, 0.1 ml for Rotor-Gene Q 5-plex HRM MDx	For use with 72-well rotor, Strip tubes, and caps	981103
Rotor-Gene Q software	Rotor-Gene Q software v2.3.1 (or higher)	
Rotor-Gene Q 5-plex HRM MDx	Real-time PCR cyclers with 5 channels, high-resolution melt analyzer, software, laptop computer, and accessories; 1-year warranty on parts and labor, installation	9002032
72-Well Rotor	For holding Strip Tubes and Caps, 0.1 ml, with reaction volumes of 10–50 $\mu$ l	9018903
Locking Ring 72-Well Rotor	For locking Strip Tubes and Caps, 0.1 ml in the 72-Well Rotor	9018904

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at [www.qiagen.com](http://www.qiagen.com) or can be requested from QIAGEN Technical Services or your local distributor.

# Document Revision History

Revision	Description
R3, September 2021	<p>Claim Extension:</p> <ol style="list-style-type: none"><li>1. Addition of testing using saliva specimens.</li><li>2. Modification of the workflow.</li><li>3. For use with 3 additional platforms and their respective software: CFX96 Dx with CFX Manager Dx Software version 3.1.3090.1022 (or higher), cobas z 480 with LightCycler 480 SW UDF version 2.0.0 (or higher), and QuantStudio 5 Dx with QuantStudio 5 Dx IVD Software version 1.0.1 (or higher).</li><li>4. The limit of detection of the 3 additional platforms (CFX96 Dx, cobas z 480, QuantStudio 5 Dx) were been added for in the performance section for the nasopharyngeal, nasal and oropharyngeal swab samples.</li><li>5. The performance characteristics section has been updated.</li><li>6. Only fluorescence channels (Green, Red, Yellow) were kept for the RGQ instrument (the dye names in brackets were deleted).</li><li>7. Only dye names were kept for CFX96 Dx, ABI7500 Fast Dx, cobas z 480, and QuantStudio 5 Dx.</li><li>8. For the ABI7500 Fast Dx, the fluorescence filters A/1, B/2, and E/5 were deleted. Only dye names were kept (Fam, Vic, and Cy5).</li><li>9. Changes to Tables 34-37 in the clinical performance section to clarify presentation.</li></ol>
R4, January 2022	Correction of typo in Table 39.
R5, September 2022	Update to Reagent Storage and Handling Update to Table 17.

#### Limited License Agreement for *artus* SARS-CoV-2 Prep&Amp UM Kit

Use of this product signifies the agreement of any purchaser or user of the product to the following terms:

1. The product may be used solely in accordance with the protocols provided with the product and this handbook and for use with components contained in the panel only. QIAGEN grants no license under any of its intellectual property to use or incorporate the enclosed components of this panel with any components not included within this panel except as described in the protocols provided with the product, this handbook, and additional protocols available at [www.qiagen.com](http://www.qiagen.com). Some of these additional protocols have been provided by QIAGEN users for QIAGEN users. These protocols have not been thoroughly tested or optimized by QIAGEN. QIAGEN neither guarantees them nor warrants that they do not infringe the rights of third-parties.
2. Other than expressly stated licenses, QIAGEN makes no warranty that this panel and/or its use(s) do not infringe the rights of third-parties.
3. This panel and its components are licensed for one-time use and may not be reused, refurbished, or resold.
4. QIAGEN specifically disclaims any other licenses, expressed or implied other than those expressly stated.
5. The purchaser and user of the panel agree not to take or permit anyone else to take any steps that could lead to or facilitate any acts prohibited above. QIAGEN may enforce the prohibitions of this Limited License Agreement in any Court, and shall recover all its investigative and Court costs, including attorney fees, in any action to enforce this Limited License Agreement or any of its intellectual property rights relating to the panel and/or its components.

For updated license terms, see [www.qiagen.com](http://www.qiagen.com).

Trademarks: QIAGEN®, Sample to Insight®, *artus*®, Prep&Amp™, Rotor-Gene® (QIAGEN Group); ATCC® (American Type Culture Collection); CFX96™, HardShell® (Bio-Rad Laboratories, Inc.); Clinical and Laboratory Standards Institute®, CLSI® (Clinical and Laboratory Standards Institute, Inc); Zepiometrix®, NAItrol™ (Cole-Parmer); Colgate®, Total SF Whitening™ (Colgate-Palmolive Company); Listerine® (Johnson & Johnson); Tussidane® (Laboratoires Des Realisations Therapeutiques Elerte); PulmoFluide® (Laboratoires Gerda); Excel® (Microsoft Corporation); Ricola® (Ricola Group); cobas®, LightCycle® (Roche Group); ABI®, MicroAmp™, EnduraPlate™, QuantStudio®, Thermo Fisher Scientific® (Thermo Fisher Scientific or its Subsidiaries); Alloids® (Wm. Wrigley Jr. Company). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

09/2022 R5 HB-2850-005 © 2021 QIAGEN, all rights reserved.

Ordering [www.qiagen.com/shop](http://www.qiagen.com/shop) | Technical Support [support.qiagen.com](http://support.qiagen.com) | Website [www.qiagen.com](http://www.qiagen.com)